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PSORIATIC ARTHRITIS
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease with heterogenic 
manifestations (Figure 1). It presents with musculoskeletal manifestations of peripheral 
arthritis, dactylitis, enthesitis, and spondylitis. Peripheral arthritis can occur in any joint; the 
pattern of arthritis in PsA is often oligoarticular (i.e. four or less joints) and asymmetrical, and 
has more often a ray pattern (i.e. joints of a single digit involved) and involvement of distal 
interphalangeal (DIP) joints than is seen in other rheumatic diseases.1, 2 Dactylitis is the 
inflammation of an entire digit, in which joints, tendons, and soft tissue are affected. This 
results in diffuse, painful swelling of a digit, and is therefore often referred to as sausage-toe or 
sausage-finger. Presence of dactylitis is very specific to PsA.3 Enthesitis is inflammation of the 
insertion of a tendon, ligament or joint capsule. Patients often present with pain at insertion 
of the Achilles tendon or plantar fascia.4 Patients with axial involvement have inflammation 
of the sacroiliac joints or the spine, either causing symptoms of chronic back pain or being 
asymptomatic.5 The pattern of musculoskeletal manifestations differs greatly between patients 
and within patients over time. 
Figure 1. Manifestations of psoriatic arthritis
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 Besides musculoskeletal manifestations, most patients with PsA also suffer from 
psoriasis. Patients have erythematous, scaling plaques that can be itchy or painful.6 These 
plaques are caused by hyperproliferation of keratinocytes, due to chronic inflammation of 
the skin. Chronic inflammation can also occur in the nails, leading to pitting, onycholysis, 
subungual hyperkeratosis and an oil-drop sign.7 Most often psoriasis is diagnosed before or 
at time of diagnosis of PsA, but in 15% of cases psoriasis is not present at time of diagnosis.8 
Of the patients with psoriasis, an estimated 6-42% of patients will eventually developing PsA,1 
at a rate of 3% per year after diagnosis of psoriasis.9 In the general population, the prevalence 
of PsA is estimated to be 0.19% in Europe and 0.13% in North America, but a lot lower in Asia 
(0.05-0.07%) and South America (0.07%).10 Both men and women are equally affected by PsA 
and patients are often diagnosed between the ages of 30 and 50 years.1
DIAGNOSIS OF PSA 
PsA is diagnosed by a rheumatologist, based on clinical assessment of PsA manifestations 
as described above, laboratory tests, and imaging. Elevation of acute phase reactants such 
as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) is seen in about half 
of the patients.11 With respect to serology, patients are usually negative for rheumatoid 
factor3, 12 and antibodies to cyclic citrullinated peptides (anti-CCP).13 No biomarkers specific to 
PsA are available. Radiographic signs of erosive disease of DIP joints, ankylosis (i.e. fusion of 
bones), new bone formation, resorption of distal phalanges, and ‘pencil in cup’ deformities are 
suggestive of PsA.14 The diagnosis of PsA varies between rheumatologists,15 which complicates 
comparing results of different study populations.
 To ensure study populations are comparable, classification criteria have been 
developed in PsA (CASPAR: ClASsification criteria for Psoriatic ARthritis).3 To meet these criteria, 
a patient must have inflammatory articular disease ( joint, spine or entheseal) and in addition 
3 out of the following 5 points: current psoriasis (2 points) or personal or family history of 
psoriasis (1 point), nail psoriasis, absence of rheumatoid factor, dactylitis either current or a 
history recorded by a rheumatologist, or radiographic evidence of juxtaarticular new bone 
formation. These criteria had a specificity of 98.7% and a sensitivity of 91.4% to diagnose PsA, 
where a clinical diagnosis was the gold standard. Patients can be classified as having one of 
five clinical patterns of PsA: distal arthritis (i.e. DIP arthritis of hand and feet), oligoarthritis, 
polyarthritis, arthritis mutilans (i.e. a destructive form of arthritis) and spondyloarthritis.16 The 
most common clinical patterns have been reported to be oligoarthritis and polyarthritis,17 but 
the clinical pattern of a patient can vary over time.1
 
Chapter 1
1 0
DIAGNOSIS OF ENTHESITIS 
Patients report pain or tenderness at insertion sites, but agreement on how to diagnose 
enthesitis in clinical practice is lacking. In clinical trials, a commonly accepted definition of 
enthesitis is entheseal tenderness at clinical examination using a scoring system, such as the 
Leeds Enthesitis Index (LEI).18 Pain at the site of the enthesis is however a sign of enthesiopathy, 
which could have degenerative, metabolic, and mechanical causes besides enthesitis.19 
Tendon complaints are quite common in the healthy population,20, 21 which complicates the 
diagnosis of PsA-related enthesitis.
 Distinguishing inflammatory enthesitis from non-inflammatory enthesiopathy might 
be done using imaging. Entheses are located superficially and can therefore easily be scanned 
with ultrasound, which has the advantage that multiple sites can be scanned. Ultrasound 
abnormalities suggestive of enthesitis are increased thickness, calcifications, enthesophytes, 
structural changes (hypoechogenicity), erosions and sonographic signs of bursitis.22 Further, 
increased vascularisation can be assessed using the power Doppler (PD) mode of ultrasound. 
Increased thickness, sonographic signs of bursitis and a PD signal are often considered 
inflammatory changes, while calcifications, enthesophytes, structural changes and erosions 
are considered structural changes.23 These abnormalities can be scored in an enthesitis 
ultrasound score for diagnostic purposes, such as the MASEI (MAdrid Sonographic Enthesitis 
Index).24 The MASEI was developed for the diagnosis in spondyloarthropathy (SpA): a score of 
18 or higher had a sensitivity of 83.3% and a specificity of 82.8% to diagnose SpA.24 Different 
studies have confirmed that the MASEI score is indeed higher in patients with SpA than in 
healthy volunteers.25, 26 
 The value of ultrasound in diagnosing enthesitis in PsA has been evaluated in a few 
studies. Eder et al. found that both structural and inflammatory MASEI scores were higher in PsA 
patients with established disease and in patients with psoriasis than in healthy volunteers.27 
Using a different scoring system, similar results were seen by Aydin at al.28 Regarding patients 
with early disease, Bandinelli et al. found more structural changes and more often a PD signal 
in early PsA than in healthy controls.29 The performance of the MASEI in early disease as 
compared with healthy volunteers or patients with established disease has not been studied 
yet. 
 The level of sonographic enthesis involvement differs greatly between patients, and is 
possibly related to disease activity or other factors influencing sonographic signs of enthesitis. 
Within PsA, it has been shown that the MASEI score was associated with LEI scores,30 but on 
the enthesis-level, concordance between ultrasound and clinical examination is generally very 
poor.31, 32 Associations with global assessment of disease activity are reported by some,33 but 
not observed by others.30, 34 A higher body mass index (BMI) and higher age were associated 
with more structural and inflammatory changes of the entheses in PsA, but also in psoriasis 
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and healthy controls.27 In healthy controls, tendons and entheses displayed PD signal after 
intense physical stress,35, 36 and preceding overuse injuries.37, 38 The role of physical activity on 
entheses as seen on ultrasound has not been studied in PsA. 
 
BURDEN OF PSA
Patients with PsA can experience loss of functional ability, decreased health-related quality of 
life (HRQOL), and loss of productivity. Disability is often assessed using the Health Assessment 
Questionnaire (HAQ) Disability Index, in which a score between 0 and 1 reflects mild to 
moderate disability, between 1 and 2 moderate to severe disability, and 2 to 3 severe to very 
severe disability. Husted et al. reported a mean HAQ of 0.58 in patients with established disease 
and The Swedish early PsA registry reported a mean HAQ score of 0.66.39, 40 In both studies, 
disability in PsA was lower than in rheumatoid arthritis (RA), though it might be argued that the 
HAQ is better in capturing disability in RA because it was first developed for use in RA. The type 
of disability experienced by patients with RA as captured with the HAQ might differ from the 
type of disability experienced by patients with PsA. Further, patients with PsA report HRQOL 
to be lower than the general population and patients with psoriasis.39, 41, 42 Both physical and 
mental aspects of HRQOL are affected and disease burden is as high as in RA and ankylosing 
spondylitis.39, 41 Impact on HRQOL has been studied in patients with established disease, but 
it is unknown to what extent this burden is already present at time of diagnosis. In two studies 
assessing which disease manifestations were associated with worse HRQOL, a relation with the 
number of tender joints but not with psoriasis was found.43, 44 Though PsA is a heterogeneous 
disease with many different manifestations, the impact of manifestations besides arthritis and 
psoriasis have not been studied. Unemployment and work disability occurs more often in PsA 
than in the general population, and is related to the level of disability.45, 46 Of the employed 
patients, about 3 out of 10 patients report having short term sick leave in the past year.47, 48 
TREATMENT
The goal of therapy is ultimately to optimize functioning and quality of life, and prevent 
structural damage. To prevent lasting structural and functional damage best, treatment should 
be started within three months if PsA is active.49 This advice is based on a concept extensively 
studied in RA but less so in PsA: the window of opportunity. Treatment in this window of 
opportunity can alter the course of disease of RA which cannot be done as effectively outside 
this window.50 It is unknown whether such a window of opportunity exists in PsA, though 
studies have shown that a short delay between onset of symptoms and diagnosis is a predictor 
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of good clinical outcomes in PsA,51, 52 and therapy is more effective in patients with a shorter 
disease duration.53, 54 
 Pharmacological treatment options in PsA are non-steroidal anti-inflammatory 
drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and local injections or 
systemic treatment with glucocorticoids. There are three types of DMARDs: conventional 
synthetic DMARDs (csDMARDs), biological agents (bDMARDs) and targeted synthetic DMARDs 
(tsDMARDs). Of the csDMARDs, methotrexate is most often used in PsA and is specifically 
preferred in case of active psoriasis. The use is widespread because of the experience with 
methotrexate in RA – in which it is known to alter the course of peripheral arthritis – and 
clinical experience in PsA, rather than because of its proven efficacy in PsA. The bDMARDs have 
effects on distinct parts of the immune system: adalimumab, certolizumab pegol, etanercept, 
golimumab or infliximab are tumor necrosis factor inhibitors (TNFi), ustekinumab inhibits 
interleukin-12/23 (IL-12/23), and secukinumab and ixekizumab inhibit IL-17. Treatment with 
tsDMARDs is targeted at a specific molecule: apremilast is a phosphodiesterase-4 inhibitor, 
and tofacitinib inhibits Janus kinase. With these many treatment options, many more being 
developed for use in PsA, and no two patients being exactly the same, choosing the best 
treatment option can be challenging. It is why groups of experts have developed guidelines to 
aid treatment decisions.
 The European League Against Rheumatism (EULAR) has developed an algorithm 
for treatment, in which different steps in therapy are taken depending on whether treatment 
was effective enough. Treatment should be escalated more quickly if adverse prognostic 
factors are present (i.e. polyarthritis, radiographic damage, elevated acute phase reactants, 
or dactylitis or other extra-articular manifestations). Treatment starts with NSAIDs, followed 
by a first csDMARD, a second csDMARD (either switch or a combination), TNFi, and lastly 
bDMARD therapy with IL-12/23 or IL-17 inhibitors, or a tsDMARDs. In case patients present 
with axial disease or enthesitis and NSAIDs do not suffice, a bDMARD should be the next step 
instead of csDMARD therapy. If patients suffer from psoriasis, topical treatment, followed 
by phototherapy and csDMARDs – especially methotrexate – are advised. Throughout the 
steps, treatment with corticosteroids can be considered as adjunctive therapy. The Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommends different 
steps of treatment escalation, depending on the manifestation, as some steps of therapy have 
not been proven to be beneficial for some of the symptoms.55 The choice of treatment should 
cover as many manifestations as possible. Though the EULAR and GRAPPA recommendations 
have some differences, both agree that treatment depends on the type of manifestations a 
patient has. With more knowledge of how each manifestation is related to burden of disease, 
treatment might be chosen more appropriately. 
 The recommendations state that therapy should be evaluated and escalated if needed, 
and an international task force recommends to do so in a treat-to-target (T2T) strategy.56 We 
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know that outcomes of patients improve if a T2T strategy is followed from experience with 
RA.57 In a T2T strategy, patients are carefully monitored and if a target of remission is not met, 
treatment is intensified. In RA, the target Disease Activity Score with 28-joint count (DAS28) is 
often used.57 It calculates a composite score based on the 28 tender and swollen joint count, 
an ESR or CRP level, and a patient’s global assessment of disease activity on a visual analogue 
scale (VAS).58 The continuous score is then translated to remission or minimal disease activity.59 
The TIght COntrol of Psoriatic ARthritis (TICOPA) trial is the only T2T trial in PsA; it has shown 
that a T2T strategy leads to better clinical and patient-reported outcomes than usual care in 
patients with PsA.60, 61 Though a T2T approach aiming at remission or – if remission cannot 
be achieved – low or minimal disease activity is also recommended in PsA, remission or low 
disease activity is not defined in PsA.49, 55, 56 
DISEASE ACTIVITY 
Composite disease activity scores
The target in a T2T strategy is a composite score, in which different aspects of disease are 
combined in a single score. In line with the goals of therapy (i.e. optimizing functioning and 
preventing structural damage), treatment is indicated if either current functioning is impaired 
due to inflammation, or if the current level of inflammation could potentially cause structural 
damage. In order to use it as a target, a disease activity measure consists of both predictors of 
future damage (e.g. joint swelling, CRP or ESR) and predictors of current disability (e.g. patient 
VAS global score). For PsA, many disease activity measures are available, though there is no 
consensus on which measure should be used for T2T in PsA. 
 In clinical trials of PsA, the DAS28 has often been used as a measure of disease 
activity.62 The use of the DAS28 has been validated RA, and the reduced joint count of 28 joints 
reflect joints that were typically affected.58 PsA, however, has a different joint distribution, and 
experts feared that disease activity in patients with predominantly involvement of DIP joints 
or joints of the feet would be missed. It is why the Disease Activity score for Psoriatic Arthritis 
(DAPSA) has been developed: a measure summing the 66 swollen joint count, 68 tender joint 
count, patient VAS global and VAS pain (both in cm, range 0-10), and CRP level.63 The clinical 
DAPSA (cDAPSA) has the same calculation but without CRP.63 PsA is however a heterogeneous 
disease, and others have argued that a composite score should be reflective of inflammation 
in all domains of disease.56 Composite scores combining multiple domains of the disease have 
been developed: the Composite Psoriatic Disease Activity Index (CPDAI),64 Psoriatic ArthritiS 
Disease Activity Score (PASDAS),65 the GRAppa Composite ScorE (GRACE),66 and the Minimal 
Disease Activity (MDA).67 The components needed to calculate all these scores are displayed in 
Table 1. 
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 The CPDAI, PASDAS and GRACE are continuous measures of disease activity using 
multiple domains of disease. In the CPDAI, severity of involvement of five domains of PsA is 
assessed and scored as not involved, or with mild, moderate or severe involvement (range 0-3 
per domain: joints, skin, entheses, dactylitis and spine). In each domain, a clinical evaluation 
is combined with patient-reported impact of disease.64 The PASDAS is calculated with a joint, 
enthesitis and dactylitis count, both patient and physician global VAS score, CRP and a SF-
36 PCS (Short Form 36 Physical Component Summary). These variables are transformed and 
weighted to result in a total score.65 The GRACE score uses joint counts, patient global, psoriasis 
and pain VAS, HAQ, PASI (Psoriasis Area and Severity Index), and PsAQoL (PsA-specific Quality 
of Life). Each of these scores are transformed to desirability function in which 0 is completely 
unacceptable and 1 is normal, and scores in between correspond to desirability states. For 
example, moderate disease activity corresponds to a desirability score of 0.63 on all scales, 
Table 1. Components in calculation of disease activity measures
DAS28 DAPSA CPDAI PASDAS GRACE MDA
Clinical Assessment       
Tender joint count 28 68 68 68 68 68
Swollen joint count 28 66 66 66 66 66
PASI x x x
LEI x x x
Dactylitis count x x
VAS physician x
Patient Questionnaire
VAS global x x x x x
VAS skin x
VAS joints x
VAS pain x x
HAQ x x x
DLQI x
BASDAI x
ASQoL x
SF-36 PCS x
PsAQoL x
Laboratory Assessment 
CRP x x  x   
DAS28: Disease Activity Score 28; DAPSA: Disease Activity index for PSoriatic Arthritis; CPDAI: Composite Psoriatic 
Disease Activity Index; PASDAS: Psoriatic ArthritiS Disease Activity Score; GRACE: GRAppa Composite ScorE; MDA: 
Minimal Disease Activity; PASI: Psoriasis Area and Severity Index; LEI: Leeds Enthesitis Index; VAS: Visual Analogue 
Scale; HAQ: Health Assessment Questionnaire; DLQI: Dermatology Life Quality Index; BASDAI: Bath Ankylosing 
Spondylitis Disease Actvitivity Index; ASQoL: Ankylosing Spondylitis Quality of Life; SF-36 PCS: Short Form 36 Physical 
Component Summary; PsAQoL: Psoriatic Arthritis-specific Quality of Life; CRP: C-reactive protein.
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which is a swollen joint count of 3, a tender joint count of 5, a HAQ score of 1.0 and VAS scores 
of 30. The average of all these desirability scores is calculated (arithmetic mean of desirability 
function: AMDF), and the GRACE score is then transformed to a 0-10 scale with a higher score 
representing higher disease activity: (1-AMDF) x 10.65, 68 
 MDA is a state rather than a composite disease activity measure. A patient is 
considered to be in MDA if at least 5 out of 7 remission criteria are met: swollen joints, tender 
joints, enthesitis count, and PASI scores have to be 1 or lower, patient VAS pain 15 or lower, 
patient VAS global 20 or lower, and HAQ 0.5 or lower.67 The remission variant is Very Low 
Disease Activity (VLDA), in which all remission criteria need to be achieved. MDA is the target 
that has been used in the only T2T trial in PsA, the TICOPA trial.60 In addition, cross-sectional 
studies have shown that patients in MDA report lower impact of disease and better HRQOL 
than patients not in MDA.69, 70 In such a cross-sectional analysis of patient outcomes however, 
it is not completely ruled out that factors not related to inflammation could lower both HRQoL 
and the probability of having low disease activity. Longitudinal data showing that achievement 
of MDA is related to an improvement of disease burden are lacking. 
 Though T2T with MDA and being in MDA are shown to be associated with better 
outcomes for patients with PsA, it is still debated whether MDA should be the target. Recently, 
a task force has recommended the use of either MDA or DAPSA in clinical practice.56
Comparison of Composite Disease Activity Scores
For all composite scores, lower disease activity is associated with a lower burden of disease 
and less structural progression. In an observational study of established PsA patients, Coates 
et al. showed that MDA is associated with less radiological progression,71 which was also seen 
in patients with low disease activity according to DAPSA, GRACE and PASDAS in data from 
a trial with golimumab.72 Using data from the same trial, it was shown that PASDAS, AMDF, 
CPDAI, DAS28, and DAPSA were all able to distinguish the treatment group from the placebo 
group.73 They were also all associated with changing treatment as a measure of active disease 
in routine clinical care.65 Michielsen et al. compared disease activity scores between patients 
finding their disease status acceptable and those who did not, and found that all the measures 
investigated (i.e. DAPSA, CDPAI, PASDAS, DAS28) were lower in patients with an acceptable 
disease status.74 
 Though all composite measures are related to indicators of inflammation, they are 
not always in agreement for a single patient: whether a patient has high disease activity and 
hence a treatment intensification is indicated depends on the measure used. In general, MDA 
is the strictest definition of low disease activity,75-79 and agreement between measures is often 
only moderate.74, 75 This disagreement between measures indicates that the question of which 
measure to choose is a relevant one; if all would give the same treatment indication, it would not 
matter which one is used. As treatment for PsA is aimed at optimizing functioning and HRQOL, 
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we need to know which composite measure best reflects these outcomes. To guide treatment 
decisions, the composite measures need to be sensitive to change when disease activity 
improves after effective treatment. In addition, most studies have assessed the performance 
of measures in observational studies of established PsA patients and in randomized clinical 
trials, but it is unknown how these measures perform in an early course of disease. Bearing in 
mind the possible window of opportunity in treatment of PsA, it is especially relevant to know 
how disease activity measures perform in that crucial early stage of disease, in current clinical 
practice.
 
DEPAR STUDY
In order to study current clinical practice of treatment, disease activity measures, and outcomes 
in patients with PsA, the DEPAR study (Dutch southwest Early Psoriatic Arthritis cohoRt) was 
set up in 2013. Patients were eligible to participate if they had a new diagnosis of PsA, were not 
yet treated with DMARDs for PsA before baseline assessment, were 18 years or older, and had 
sufficient understanding of the Dutch language. DMARD treatment with indication of psoriasis, 
and use of NSAIDs were allowed. Classification criteria were not included in the eligibility 
criteria, to ensure a sample representative of daily clinical practice. In the first year, patients 
were seen by their rheumatologist every 3 months and subsequently visited a research nurse 
for clinical evaluation. They were asked to complete questionnaires shortly before or after their 
visit. Laboratory values were collected every 3 months, and radiographs of hand and feet were 
collected yearly. Though the data of the first year of follow up are analysed in this thesis, the 
DEPAR study also collects data after 18 and 24 months, and yearly after that.
 
OBJECTIVES AND OUTLINE OF THIS THESIS 
In order to improve outcomes for patients with PsA, good measures of disease activity are 
needed. As we suspect the chances to change the disease course are highest soon after 
diagnosis, more information on disease activity and outcomes at time of diagnosis and 
immediately after diagnosis is needed. Therefore, the aims of this thesis are to investigate in 
early PsA:
• ultrasound abnormalities of the entheses
• burden of disease at time of diagnosis and its relation with disease manifestations
• the relation between time to minimal disease activity and outcomes
• performance of disease activity measures
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 First, we explore whether ultrasound could aid in the diagnosis of enthesitis in PsA. 
We show the results of a comparison of extremes in Chapter 2: we compare the prevalence 
of ultrasound abnormalities of the entheses at time of diagnosis of PsA, in patients with 
established disease, and in young, healthy volunteers. These results are then validated 
in Chapter 3, in which we compare established disease with older healthy volunteers. In 
addition, we investigate which factors are associated with ultrasound abnormalities of the 
entheses in patients with established PsA. 
 In Chapter 4 we study the impact of PsA on HRQoL at time of diagnosis in a cross-
sectional analysis, and assess which of the disease manifestations are related with higher 
impact of disease. 
 The longitudinal relation between achieving a state of MDA and burden of disease 
in the first year after diagnosis is studied in Chapter 5. We also investigate whether time to 
achieving MDA is related to better outcomes. 
 We then proceed to comparing different disease activity measures. In Chapter 6 we 
describe low disease activity 1 year after diagnosis of PsA using 2 disease measures recently 
recommended for use in clinical practice: MDA and DAPSA. These 2 measures are compared 
by assessing burden of disease in the different definitions of low disease activity. Chapter 7 
shows a comparison of the performance of multiple disease activity measures in early PsA. 
 In Chapter 8, these results, their implications on clinical practice and suggestions for 
future research are discussed. 
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ABSTRACT
Objectives: We aimed to describe sonographic structural and inflammatory changes in 
entheses of patients with recently diagnosed psoriatic arthritis (PsA), patients with established 
PsA, and young healthy volunteers, and to investigate whether the MAdrid Sonographic 
Enthesitis Index (MASEI) enables us to distinguish these groups in an extreme comparison. 
Method: New and established PsA patients and healthy volunteers (aged 20-30 years) were 
recruited. The triceps, quadriceps, patellar, Achilles and elbow extensor tendon insertion, and 
plantar fascia entheses were investigated sonographically for structural changes, erosions, 
calcifications, increased thickness, bursitis, and power Doppler (PD) signal according to the 
MASEI. 
Results: The study included 25 new and 25 established PsA patients, and 25 healthy volunteers. 
Increased thickness and PD signal in knee entheses were common for patients and healthy 
volunteers, while changes at other locations predominantly occurred in patients only. PD was 
recoded (1, 1 spot; 1.5, 2 or 3 spots; 2,confluent signal; 3, severe confluent signal) and thickness 
of knee entheses excluded. This resulted in different modified MASEI scores between PsA 
patients and young healthy controls: median (interquartile range) modified MASEI of 13 (10-
22.5) in new PsA, 13.5 (9.5-18) in established PsA, and 3 (1-8.5) in healthy volunteers (p = 0.002).
Conclusions: Structural ultrasound changes and PD in entheses are common in both new 
and established PsA and healthy controls. MASEI score did not differentiate PsA patients 
from young healthy volunteers. After recoding of PD severity and excluding thickness of knee 
entheses, marked differences between PsA patients and healthy controls were observed. 
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INTRODUCTION
Enthesitis is an entry criterion of the ClASsification criteria for Psoriatic ARthritis (CASPAR) 
criteria.1 It is an inflammation of tendon, ligament or joint capsule insertion, with an estimated 
prevalence of 25% to 78% .2 The presentation is similar to other tendon complaints that are 
quite common in the healthy population.3 Therefore, general practitioners, dermatologists, 
and rheumatologists do not always recognize the presence of enthesitis or its association with 
psoriatic arthritis (PsA).2 
 In research, enthesitis is scored by counting the number of tender entheses. 
Tenderness does not occur in inflammatory enthesiopathy alone.4, 5 Other means may help to 
differentiate inflammatory from non-inflammatory entheseal tenderness. Ultrasound can be 
used to investigate multiple superficially located entheses. Abnormalities can be quantified 
with a combined score, for example the MAdrid Sonographic Enthesitis Index (MASEI).6
 The main objective of this cross-sectional study was to investigate the frequency 
of ultrasound changes at the entheses of patients with recently diagnosed PsA, patient with 
established PsA, and young healthy volunteers (aged 20-30 years). In this extreme comparison, 
we aimed to describe sonographic signs of enthesitis in clearly diseased and clearly non-
diseased entheses. The secondary objective was to investigate whether an enthesitis score 
(using the MASEI) was able to distinguish the 3 groups. We chose a control group of young 
healthy volunteers because their tendons have matured but have had limited exposure to the 
other causes of enthesiopathy.
METHOD
Patients and setting
Three groups of participants were investigated: new PsA patients, established PsA patients and 
healthy volunteers (aged 20-30 years). Consecutive newly diagnosed and established patients 
were included in hospitals in the south-west of the Netherlands. Established disease was 
defined as having been diagnosed with PsA for at least 2 years. Those patients were included 
irrespective of disease activity. To reduce the impact of age on ultrasound readings and clinical 
evaluation, an age limit of 55 years was set in the established PsA group. Healthy 20-30-year-
old volunteers were recruited via advertisement at the medical faculty and by word of 
mouth. Exclusion criteria for healthy volunteers were familiar hypercholesterolemia, diabetes 
mellitus, and having any rheumatological disease. Participants were recruited from May 2015 
to January 2016. Written informed consent was obtained from all participants according to 
the Declaration of Helsinki. The study was approved by the local medical research ethics 
committee of Erasmus MC, University Medical Center Rotterdam, the Netherlands (MEC-2012-
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Data collection
Ultrasound examination of the entheses was performed by a trained sonographer (KW) who 
was blinded to the clinical information. An Esaote MyLab60 with the Probe LA-435 (6-18 MHz; 
Doppler frequency of 8.3 MHz, pulse repetition frequency of 750 Hz and a wall filter of 3) and 
Probe LA-523 (4-13 MHz; 6,3 MHz, 750 Hz and a wall filter of 4) was used. A color gain was 
set at the disappearance of color noise in the bone underneath the enthesis. The 6 MASEI 
locations and the common extensor insertion at the lateral epicondyle of the elbow (increased 
thickness cut-off 4.2 mm7) were assessed bilaterally. Each ultrasound location was scored for 
calcifications, erosions, increased thickness, structure, power Doppler (PD) signal, and bursitis, 
in accordance with the MASEI.6 
 Positioning of patients followed the recommendations of the MASEI developers, 
but with the knee flexed at approximately 30° instead of 70° in order to improve PD signal 
detection.8 The lateral epicondyle was examined in 90° elbow flexion. PD was scored with a 
semi-quantitative scoring system similar to the method used in arthritis:9 0, absent; 1, 1 color 
spot; 1.5, 2 color spots; 2, confluent signal; and 3, severe signal (Supplemental Figure 1). 
Interrater agreement of rescoring was 93% and weighted Cohen’s kappa with linear weights 
was 0.92. 
Statistical methods
Simple descriptive techniques fitting the distribution were used to describe the study results 
and determine whether ultrasound data differed in the 3 groups, in STATA 14.0. 
RESULTS
Participants
In total, 75 participants were evaluated: 25 new PsA and 25 established PsA patients, and 25 
young healthy volunteers. Median disease duration was 2.9 weeks in new PsA and 8.0 years 
in established PsA (Table 1). Median symptom duration of musculoskeletal complaints as 
reported by the new patients was 1.2 years (interquartile range [IQR] 0.6-3.1 years).
Structural ultrasound findings
Calcifications were seen in all locations of entheses in patients, with the highest prevalence at 
the lateral epicondyle (entheses of new 56% vs established 28%), quadriceps tendon (68% vs 
50%), and Achilles tendon (70% vs 56%) (Table 2 and Supplemental Table 1). In entheses of 
healthy volunteers, calcifications were seen far less frequently and they mainly occurred in the 
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quadriceps tendon (30%). Increased thickness was seen at all locations in patient entheses, 
with the highest prevalence at the lateral epicondyle (entheses of new 80% vs established 
74%) and at the knee entheses (prevalence range 52-82%). In healthy volunteers, only knee 
entheses had an increased thickness (range 50-70%). 
Table 1. Participant characteristics of the three groups 
New PsA 
(n=25)
Established PsA 
(n=25)
Healthy volunteer 
(n=25)
Male, n (%) 13 (52) 13 (52) 12 (48)
Age, years, median (range) 52 (30-72) 44 (26-53) 22 (20-26)
Time since PsA diagnosis, median (IQR) 2.9 (0.7-5.3) weeks 8.0 (5.0-11.0) years  
Medication, n (%)    
DMARDs 4 (16)* 17 (68)  
Biologicals 0 (0) 5 (20)  
DMARDs and biologicals 0 (0) 3 (12)  
LEI, median (IQR) 1 (0-1) 1 (0-2) 0 (0-0)
MASES, median (IQR) 0 (0-4) 1 (1-3) 0 (0-0)
*all DMARD use duration < 1 week. 
PsA: psoriatic arthritis; IQR: interquartile range; DMARD: disease-modifying antirheumatic drug; LEI: Leeds Enthesitis 
Index (range 0-6); MASES: Maastricht Ankylosing Spondylitis Enthesis Score (range: 0-13). 
Inflammatory ultrasound findings
The majority of patients and half of the healthy volunteers had a PD signal present in at least 
1 enthesis (Table 3, Supplemental Table 2). A PD score of 2 or more in at least 1 enthesis was 
present in 52% of new and 44% of established PsA patients, and in 28% of healthy volunteers. 
The lateral epicondyle and the quadriceps tendon were affected in one-third of the entheses 
in patients (Table 2). In healthy volunteers, one-third of the quadriceps entheses and distal 
patellar entheses showed a PD signal. 
MASEI
The median MASEI score with the lateral epicondyle added was 18 (IQR 15-31) in new PsA, 22 
(IQR 15-27) in established PsA, and 10 (IQR 5-15) in healthy volunteers (p = 0.002). As described 
before, the main contributors to the MASEI scores in healthy volunteers were increased 
thickness and PD signal in knee entheses. After we excluded knee entheseal thickness and 
used the new PD scores, the IQRs were no longer overlapping. The scores of the modified 
MASEI were 13 (IQR 10-22.5), 13.5 (IQR 9.5-18) and 3 (IQR 1-8.5, p = 0.002) (Table 3). 
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Table 2. Madrid Sonographic Enthesitis Index (MASEI) score per component per enthesis location (n=50 per group)
Structure Thickness Erosion
 A B C  A B C  A B C
Lateral epicondyle tendon  4   80 74 20   2  
Triceps tendon 2 2   16 14 2   6 4
Quadriceps tendon 2 8 2  66 56 50    2
Proximal patella tendon  4   52 60 58   2  
Distal patella tendon  12   82 74 70   2  
Achilles tendon     8 26   4 8 4
Plantar fascia     24 28 4     
Calcification* PD signal Bursitis
 A B C  A B C  A B C
Lateral epicondyle tendon 56 28 8  36 34      
Triceps tendon 16 22 2   10      
Quadriceps tendon 68 50 30  28 30 34     
Proximal patella tendon 22 12 6  8 12 2     
Distal patella tendon 18 16   16 14 30     
Achilles tendon 70 56 8  8 10 2  8 6  
Plantar fascia 16 2 6         
Data are shown as the number of abnormalities (%) per group. A: new PsA patients; B: established PsA patients; C: 
healthy volunteers. 
*Calcification is expressed as the number of tendons with a score > 0. PD: power Doppler.
Table 3. Outcome of the Madrid Sonographic Enthesitis Index (MASEI) scoring system and different adjustments to 
the MASEI scoring system in the 3 participant groups
 new PsA  
(n=25)
established PsA 
(n=25)
healthy volunteer 
(n=25)
Ultrasound Examination    
MASEI* 15 (11-25) 16 (11-26) 10 (5-13)
PD    
PD in any enthesis 76% 96% 56%
PD≥2 in any enthesis 52% 44% 28%
≥ 3 entheses with PD 20% 32% 24%
Amendments (stepwise)    
 + Lateral epicondyle 18 (15-31) 22 (15-27) 10 (5-15)
 - Quadriceps thickness 13 (11-28) 17 (12-23) 5 (2-12)
 Amending PD score# 13 (10-22.5) 13.5 (9.5-18) 3 (1-8.5)
Data are shown as median (interquartile range) or percentage of participants. 
*Range 0-136. 
#Using new scoring system to award points for PD: 1a was given 1 point and 1b 1.5 points. PsA: psoriatic arthritis; PD: 
power Doppler.
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DISCUSSION
Sonographic changes in the entheses were observed in young, healthy volunteers, patients 
with recently diagnosed PsA, and patients with established PsA. Increased thickness and a 
subtle positive PD signal in knee entheses were common in healthy volunteers and patients, 
while abnormalities at other locations predominantly occurred in patients. After we excluded 
patellar tendon enthesis thickness and applied a new method of scoring PD, the modified 
MASEI was able to distinguish between PsA patients and healthy controls. Furthermore, we 
showed that ultrasound abnormalities are already very common in early PsA.
 The extreme contrast we expected between young healthy volunteers and PsA was 
not reflected in the MASEI score. We chose to compare PsA patients and clearly non-diseased 
young subjects, expecting a big contrast owing to difference in disease status and age. Tendon 
thickness reference values explained part of the overlap, especially in the case of the knee 
entheses. The reference values originate from an ultrasound study of human cadaveric limbs 
aged 67-87 years10 and probably underestimate enthesis thickness. Small spots of PD signal 
in healthy volunteers further diminished the expected extreme contrast. Our findings seem to 
suggest that a single spot of PD is not of value in identifying active entheseal inflammation and 
that at least a confluent signal is necessary. Furthermore, the patellar tendon is susceptible to 
showing hypervascularity after acute physical stress. A study performing PD examination on 
runners showed hypervascularity in the patellar tendon directly after a marathon.11
 Our results raise questions and challenges for the future. First, our controls were 
not age-matched. Therefore, the differences between controls and patients cannot solely be 
ascribed to entheseal inflammation due to PsA. The effect of aging is likely to play a role as 
well, which is also reflected in higher scores in the slightly older new PsA group. The effect 
of factors such as obesity, physical exercise, age, and gender could not be analyzed, as the 
subgroups would be too small to analyze. Secondly, compared to other studies in early PsA, 
we found slightly higher scores on PD, possibly due to differences in study design and the 
machines used.12, 13
CONCLUSION
Ultrasound structural changes and inflammation in the enthesis were common in both new 
and established PsA patients, and in the knees of healthy young adults, using the MASEI score. 
Excluding knee entheses thickness and refinement of PD signal scores provided discrimination 
of PsA from healthy young volunteers in terms of enthesis pathology.
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Supplemental Figure 1. Recoding of power Doppler score within 2 mm of the cortex
1a (1 color spot) for A, 1b (2 color spots) for B, 2 (confluent signal) for C and 3 (severe signal) for D. Ultrasound of lateral 
epicondyle of the humerus (A-C) and quadriceps insertion (D)
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ABSTRACT
Objective: Enthesitis is a manifestation of psoriatic arthritis (PsA), but its symptoms are 
difficult to interpret clinically. We investigated the associations of untrasonographic changes 
in entheses with clinical characteristics in PsA patients, and compared enthesis changes of PsA 
patients aged 35 to 60 with healthy volunteers of that age.
Methods: Consecutive PsA patients participated in this cross-sectional study, irrespective 
of enthesitis complaints and age. We collected data about complaints, physical activity and 
activity avoidance, medication, and clinical enthesitis. Inflammatory and structural enthesis 
changes were scored with the modified MAdrid Sonographic Enthesitis Index (MASEI). Among 
all PsA patients, associations between ultrasound scores and clinical characteristics were 
investigated using linear regression. We compared ultrasound scores of healthy volunteers 
and PsA patients aged 35 to 60 years using Wilcoxon rank tests.  
Results: Eighty-four PsA patients and 25 healthy volunteers participated. In PsA patients, we 
found a small association between higher inflammatory modified MASEI score and higher 
age (β:0.07, 95% CI:0-0.13) and current use of biologicals (β:1.56 95% CI 0.16-2.95). Patients 
reporting avoiding activities had significantly lower inflammatory modified MASEI scores (β:-
1.71, 95% CI:-3.1;-0.32) than those who did not. The PsA patients aged 35 to 60 years (n=50) 
had similar inflammatory scores as healthy volunteers, but higher structural scores (median 
6 vs. 2, p=0.01).
Conclusion: Within PsA patients, avoiding physical activity, younger age and not using 
biologicals was associated with less entheses inflammation. PsA patients and healthy 
volunteers aged 35 to 60 years displayed similar levels of inflammatory changes of the 
entheses, but PsA patients had more structural damage. 
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease that belongs to the 
group of spondyloarthropathies. It has a heterogeneous presentation of arthritis, psoriasis, 
spondylitis, dactylitis and enthesitis.1, 2 Enthesitis is one of the distinguishing features of 
spondyloarthropathies and is defined as inflammation of tendon, ligament or joint capsule 
insertion. Enthesitis is found at clinical examination in a third of PsA patients,3 but tenderness 
of the enthesis does not necessarily have an inflammatory origin. A better technique is 
needed to distinguish PsA-related inflammatory enthesitis from other enthesiopathies, such 
as metabolic, degenerative and mechanical processes.4
 With ultrasound, inflammatory and structural changes of the entheses can be 
assessed5 and quantified with a composite ultrasound score, such as the MAdrid Sonographic 
Enthesitis Index (MASEI).6 In a previous study we evaluated the value of use of the MASEI in 
an extreme comparison; we compared patients newly diagnosed with PsA, patients with 
established disease and young healthy volunteers.7 We found that increased thickness of 
knee entheses and a subtle power Doppler (PD) signal were present in all groups, even in 
young healthy volunteers. We, therefore, modified the MASEI score: we excluded knee enthesis 
thickness (i.e. quadriceps and both patellar tendon insertions) from the evaluation and graded 
PD severity. This modified MASEI score showed a good discrimination between entheses of 
patients and those of young healthy volunteers. As the number of enthesis abnormalities 
varied within all groups, we suspected other factors than PsA-related inflammation could 
cause these ultrasound abnormalities. Previous studies, for example, showed that higher 
age and higher body mass index (BMI) were associated with more entheseal abnormalities 
on ultrasound both in PsA patients and in healthy volunteers.8, 9 Studies in healthy volunteers 
showed that physical activity is also associated with changes in entheses on ultrasound,10, 11 
although this is not confirmed in PsA to our knowledge. We, therefore, aimed to investigate 
associations between modified MASEI scores and clinical characteristics in an average PsA 
population. In addition, we aimed to compare the modified MASEI scores of PsA patients and 
healthy volunteers aged 35 to 60.
METHODS
Patients and Setting
Consecutive patients of all ages with established PsA for at least 2 years attending the 
rheumatology clinic were eligible to participate, irrespective of disease activity or complaints. 
Patients were recruited from 3 outpatient clinics in The Netherlands (the academic hospital 
Erasmus MC, and the general hospitals Vlietland hospital and Albert Schweitzer hospital) 
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between May and August 2016. Healthy volunteers were invited if they were aged 35 to 60 
years, without a history of any of the following: any rheumatic disease, Crohn’s disease, uveitis, 
familial hypercholesterolemia or diabetes. Written informed consent was obtained from all 
participants according to the Declaration of Helsinki. The study was approved by the local 
medical research ethics committee of Erasmus MC, University Medical Centre Rotterdam, The 
Netherlands (MEC-2012-549).
Data collection
In a structured interview, patients answered questions about their disease duration, physical 
activity and avoidance of activity. Regarding physical activity, patients were asked whether 
they exercised regularly. With respect to avoidance, patients were specifically asked whether 
they avoided activities due to complaints or fear of complaints in daily life during exercise, 
work, household activities and chores. We scored avoidance when patients reported avoiding 
activities because of pain or fear of pain. Fulfilment of Classification criteria for PsA (CASPAR) 
criteria12 and medication use was obtained from chart review. 
Data collected during physical examination were height, weight, 66 swollen joint 
count, 68 tender joint count, enthesitis at clinical examination (Leeds Enthesitis Index, LEI and 
Maastricht Ankylosing Spondylitis Enthesitis Score, MASES), and Psoriasis Area and Severity 
Index (PASI). 
Ultrasound examination was performed directly after clinical examination by a 
sonographist trained in enthesis sonography (IH), who was blinded for clinical information. 
Patients were instructed not to communicate any clinical information to the sonographist by 
the researchers who conducted the interview and physical examination (MM, KW). The 6 MASEI 
entheses and the lateral epicondyle were bilaterally examined using an Esaote MyLab60 with 
linear probes LA435 (6-18 MHz; Doppler frequency of 8.3 MHz, pulse repetition frequency of 
750 Hz and a wall filter of 3) and LA532 (4-13 MHz; 6,3 MHz, 750 Hz and a wall filter of 4). The 
former was used for entheses of the upper limbs and the latter for the entheses of lower limbs. 
In each site, we scored calcifications, erosions, structural changes, thickness, Power Doppler 
(PD) signal and bursitis. Only presence of PD signal within 2 mm of the cortex was scored. 
Patients were positioned according to the MASEI, but with the knee flexed at approximately 
30° (rather than 70°) and resting on a pillow to ensure relaxing of the quadriceps muscle. 
The lateral epicondyle was examined in 90° flexion and a cut off of 4.2 mm was used in this 
enthesis.13 If a PD signal was present, images of the severest PD signal were saved and scored 
by KW and IH, who had an interrater agreement of 93% (intraclass correlation coefficient). 
Besides the original MASEI score, we calculated the modified MASEI by excluding the knee 
entheses thickness (i.e. quadriceps and proximal and distal patellar tendon insertion) and 
grading of PD signal. All abnormalities were recorded during ultrasound evaluation, and PD 
signal was graded by a second scorer (KW) on the static images. PD signal intensity was scored: 
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0: absent, 1: 1 spot, 1.5: 2 spots, 2: confluent signal, 3: confluent severe signal (Supplemental 
Figure 1). Absolute agreement was 93% and weighted Cohen’s kappa using linear weights was 
0.92. We distinguished an inflammatory component (sum of points for increased thickness, 
bursitis and PD signal) and structural component (sum of points for structure, calcifications/
enthesophytes and erosions). 
Statistical analysis
Within the total PsA population, the association between clinical characteristics, and 1) 
inflammatory modified MASEI and 2) structural modified MASEI were investigated using 
multiple linear regression analyses. Using a forward selection (p<0.30), the following 
independent variables were tested: age, BMI, disease duration (square-transformed), current 
use of disease modifying antirheumatic drugs (DMARDs), current use of nonsteroidal anti-
inflammatory drugs (NSAIDs), current use of biologicals, avoidance of activities, exercise and 
enthesitis at clinical examination. This was done for both inflammatory modified MASEI and 
structural modified MASEI as dependent variable. The latter was transformed ([y+1]2) because 
of its skewed distribution. Modified MASEI scores of a subgroup of patients between the age 
of 35 and 60 and of the healthy volunteers of the same age-range were compared using the 
Wilcoxon rank-sum test.
RESULTS
In total, 84 consecutive patients with established PsA participated; mean age was 55 years 
(standard deviation [SD] 11, age range 26 to 76), 45 (54%) were male and mean BMI was 27 (SD 
5). Median disease duration was 8 years. Disease activity was mild in our usual care consecutive 
cohort: median swollen joint count was 0 (interquartile range [IQR] 0-2) and median tender 
joint count 3 (IQR 0-7). Median LEI score was 0.5 (IQR 0-2). Forty patients (48%) reported to 
exercise regularly and avoiding activities was reported by 17 (43%) of those patients with 
regular exercise. Among patients not exercising regularly, avoidance of any physical activity 
was reported by 28 (64%, Table 1). 
Association between ultrasound scores and clinical characteristics
Within patients, a small association was found between a higher inflammatory modified MASEI 
score and 1) higher age (β 0.07, 95% CI 0-0.13) and 2) current use of biologicals (β 1.56 95% 
CI 0.16-2.95). Patients that reported to avoid activities had significantly lower inflammatory 
modified MASEI scores (β -1.71, 95% CI -3.1;-0.32, Table 2). Higher age was also associated with 
a higher score on structural modified MASEI (β 0.03, 95% CI 0.01-0.05, p=0.001, Table 3). Current 
use of NSAIDs or DMARDs, regularly exercising, gender and enthesitis at clinical examination 
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Table 1. Demographic and clinical characteristics of patients
Age, yrs 55 ± 11
Male 45 (54)
BMI 27 ± 5
Disease duration, yrs 8 (5-12)
Fulfilling CASPAR criteria 81 (96)
Swollen joint count (66) 0 (0-2)
Tender joint count (68) 3 (0-7)
LEI 0.5 (0-2)
MASES 1 (0-2)
PASI* 0.6 (0-2.8)
Regularly exercising 40 (48)
Avoidance 45 (55)
Current medication use
NSAID 31 (37)
DMARD 64 (76)
Prednisone 1 (1)
Biological DMARD 40 (48)
Data presented as mean  ± standard deviation, n (%) or median (interquartile range). 
*excluding 1 patient without a history of psoriasis
PsA: psoriatic arthritis; BMI: body mass index; CASPAR: Classification criteria for psoriatic arthritis; LEI: Leeds enthesitis 
index; MASES: Maastricht ankylosing spondylitis enthesitis score; PASI: psoriasis area and severity index; NSAID: non-
steroidal anti-inflammatory drug; DMARD: disease modifying anti-rheumatic drug.  
Table 2. Association between ultrasound scores (inflammatory modified MASEI) and clinical characteristics 
 β (95% CI) p-value
Age 0.07 (0;0.13) 0.050
BMI 0.13 (-0.01;0.27) 0.063
Duration2 0.04 (-0.73;0.82) 0.909
DMARD no vs yes 1.23 (-0.4;2.87) 0.137
Biological no vs yes 1.56 (0.16;2.95) 0.029
Avoidance no vs yes -1.71 (-3.1;-0.32) 0.017
Linear regression of 84 patients 
BMI: body mass index; DMARD: disease modifying antirheumatic drug; CI: confidence interval.
Table 3. Association between ultrasound scores (structural modified MASEI) and clinical characteristics  
 β (95% CI) p-value
Age 0.03 (0.01;0.05) 0.001
BMI 0.04 (0;0.08) 0.054
Duration2 0.11 (-0.1;0.32) 0.302
Linear regression of 84 patients. Transformation of structural modified MASEI: (y+1)2. 
BMI: body mass index; CI: confidence interval.
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were not associated with any of the modified MASEI scores. 
Enthesis ultrasound scores
Total ultrasound scores of patients aged 35-60 years were compared with those of 25 healthy 
volunteers in the same age range. Healthy volunteers had a mean age of 47 (SD 6) years, 12 
were male (48%) and average BMI was 25 (SD 4, Supplemental Table 1). The original median 
(IQR) MASEI scores of 50 PsA patients aged 35-60 years (14 [9-21]) were comparable to those 
of the 25 healthy volunteers (13 [9-18], Table 4). The prevalence of each abnormality in the 
total PsA group, in the subgroup aged 35 to 60, and in the healthy volunteer group is shown in 
Table 5. After excluding knee enthesis thickness and grading PD score, the resulting modified 
MASEI scores were 11 (IQR 6.5-15) in patients and 7.5 (IQR 5-9, p = 0.01) in healthy volunteers. 
The inflammatory contribution (i.e. thickness, bursitis and PD signal) to this modified MASEI 
was similar in patients (5 [IQR 2-7]) and healthy volunteers (3.5 [IQR 2-5.5]). The structural 
contribution (i.e. calcification, erosion and structural changes) was significantly higher in 
patients (6 [IQR 3-10]) than in healthy volunteers (2 [IQR 1-6], p = 0.01). Presence of PD signal 
was similar in patients and healthy volunteers.
Table 4. Comparison of enthesitis ultrasound scores between patients with psoriatic arthritis and healthy volunteers
Total PsA patients 
(n=84)
PsA patients aged 
35-60 years 
(n=50)
Healthy volunteers 
aged 35-60 years 
(n=25)
p-value 
PsA vs. HV 
aged 35-
60 years
MASEI 15.5 (11-22) 14 (9-21) 13 (9-18) 0.39
Modified MASEI 12 (7.3-17) 11 (6.5-15) 7.5 (5-9) 0.005
Inflammatory modified MASEI 5 (2.8-7.5) 5 (2-7) 3.5 (2-5.5) 0.16
Structural modified MASEI 7 (3-10) 6 (3-10) 3 (1-6) 0.005
PD
PD in any enthesis 74 (88) 44 (88) 22 (88) 1.00
PD in two or more enthesis 47 (56) 27 (54) 17 (68) 0.25
Confluent PD in any enthesis 35 (42) 20 (40) 9 (36) 0.74
Severe PD in any enthesis 7 (8) 4 (8) 0 (0) 0.29
Average PD score* 1.5 (1.3-1.8) 1.5 (1.3-1.7) 1.5 (1.3-1.5) 0.44
Data presented as median (interquartile range) or n (%). 
*in 74 and 44 patients and 22 healthy volunteers where PD was present
MASEI: Madrid sonographic enthesitis index; modified MASEI: MASEI with lateral epicondyle, excluding knee enthesis 
thickness and grading of power Doppler; PD: power Doppler, HV: healthy volunteers. 
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Table 5. Madrid Sonographic Enthesitis Index (MASEI) score per component per enthesis location 
Structure Thickness Erosion
 A B C  A B C  A B C
Lateral epicondyle tendon 1 1 53 50 30 4 3
Triceps tendon 1 2 13 11 2 3
Quadriceps tendon 70 64 60
Proximal patella tendon 1 1 74 72 68 1 1
Distal patella tendon 96 98 1 1
Achilles tendon 1 1 10 12 2 2 3
Plantar fascia     33 23 12     
Calcification* PD signal Bursitis
 A B C  A B C  A B C
Lateral epicondyle tendon 49 41 16 26 30 18
Triceps tendon 24 23 2 1 2 2
Quadriceps tendon 65 66 48 34 32 42
Proximal patella tendon 8 7 2 11 10 12
Distal patella tendon 10 8 14 53 30 36
Achilles tendon 52 55 42 5 4 4
Plantar fascia 1           
Data are shown as the number of abnormalities (%) per group. A = total PsA group, B = PsA of 35 to 60 years of age, 
C = healthy volunteers of 35 to 60 years of age. *Calcification is expressed as the number of tendons with a score >0. 
PD: power Doppler.
DISCUSSION
We found that in a PsA population not selected based on complaints of the entheses, higher 
age and the current use of biologicals were associated with higher inflammatory scores, 
while patients reporting avoidance of activity had lower inflammatory scores. More structural 
changes in PsA was associated with higher age only. No effects of BMI, current NSAIDs use, 
regular exercise, gender and clinical symptoms of enthesitis on ultrasound were seen, possibly 
because we did not have the power to detect a small effect. Inflammatory changes of the 
entheses occurred as often as in healthy volunteers of the same age. The PsA patients did 
however have twice as many structural changes of the entheses. 
 The finding that regular exercise was not related to ultrasound changes but 
avoidance of activity was related seems contradictory. This may relate to the way we recorded 
avoidance, namely in more domains than only sport activities and patients could both report 
avoiding activity and exercising regularly. In the statistical analysis ultrasound changes were 
stronger associated with avoidance than with physical activity. Physical activity is probably 
both influencing and influenced by pathology of tendons and entheses, which makes the 
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interpretation of sonographic abnormalities difficult. Some patients avoiding physical activity 
might have suffered from enthesitis and consequently altered their behaviour. The relation 
between physical activity and sonographic enthesis changes has not been shown in PsA 
before, although some work has been done in athletes. Changes of tendons and entheses 
on ultrasound have been observed in the patellar tendon of athletes immediately after  their 
high-level badminton matches,10 and after they ran a marathon.11 Their respective strain on 
the tendon might be different, but, in both, some reaction after physical exercise was seen 
on ultrasound. This could be a physiological response or an early sign of a pathological 
reaction: other studies have shown that abnormalities on ultrasound could precede clinical 
manifestations of overuse injuries in healthy athletes.14, 15 In contrast, a study assessing the 
MASEI scores of 30 athletes (who were running or playing soccer for at least 6 hours per week) 
and 29 non-athletes (who were playing a sport less than 1 hour per week) were not able to 
show a difference.16 These data suggest that in a healthy situation tendons and entheses have 
adapted to the regular level of physical activity but do respond to a change in physical activity. 
We found a similar relation in PsA patients, though we did not directly study the modifying 
effect of PsA by comparing the relation with that in healthy volunteers. Longitudinal studies 
are needed to investigate whether the response of entheses to physical activity is altered in 
PsA.
 Comparable inflammatory scores of healthy volunteers and PsA patients suggest that 
ultrasound evaluation of the enthesis is of limited value in screening for inflammation. This 
was also concluded by Groves et al., who compared MRI and ultrasound evaluation of the 
elbow in patients with PsA and rheumatoid arthritis who reported elbow pain.17 In a third of 
cases, inflammation could be seen on MRI but not on ultrasound. The larger extent in which 
structural changes were present in PsA patients in our study suggests that patients have been 
subject to more chronic inflammation of the entheses than healthy volunteers of similar age. 
 The higher occurrence of inflammatory changes of the entheses in patients using 
biological DMARDs was an interesting but unexpected finding as biological DMARDs are 
recommended in the treatment of enthesitis in PsA. One explanation is that patients on 
biological DMARDs are a selected population with more severe inflammation. Michelsen et 
al. investigated Achilles enthesitis in PsA patients and found use of biologicals was associated 
with more structural damage, but not with inflammatory activity.18 This contradicts our study, 
as we found an association with inflammatory activity and not with structural damage. A 
second possible explanation is that tendons and entheses recover at a slow rate and not all 
patients may have used biological DMARDs for a long enough period. A study in ankylosing 
spondylitis showed that inflammatory ultrasound lesions did not change after 6 months of 
tumor necrosis factor blocking therapy.19 In a similar study, Ayden et al., however, did find 
a decrease in ultrasound lesions after 2 months of therapy and so did Naredo et al. after 6 
months of follow up.20, 21 Similarly, a study using MRI in axial spondyloarthritis found a decrease 
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in enthesitis after 2 years of treatment with etanercept.22 A third explanation is that the effect of 
biological DMARDs on enthesitis is heterogeneous and depends on the type of treatment (i.e. 
TNF inhibitors, anti-IL17 or anti-IL12/IL23). 
 A limitation of our study is its cross-sectional design, which makes the interpretation 
of the association between clinical symptoms and ultrasound scores difficult. The relation 
between physical activity and enthesitis might be subject to information bias and the exact 
impact of physical activity on entheses is better investigated in an experimental setting. 
For example, the reporting of physical activity and avoiding of physical activity might be 
influenced by a history of enthesitis and different adaptive behaviour and coping strategies. 
Second, physical activity and in particular long-term effects of physical activity are difficult to 
measure and the measurement of self-reported physical activity could be biased. Third, this 
study has an exploratory nature, in which multiple factors of influence were tested. The models 
were fitted to this established usual care population with relatively low disease activity and 
use of NSAIDs and biologicals by the majority. For these reasons, future studies – preferably 
longitudinal studies – are needed to confirm these results. 
 In conclusion, in this cross-sectional study, avoiding physical activity, younger age 
and not using biological DMARDs were associated with less inflammation of the entheses. 
PsA patients and healthy volunteers aged 35 to 60 years display similar levels of inflammatory 
changes of the entheses, but PsA patients had more structural damage. The only way 
to understand these associations is to investigate changes of entheses on ultrasound in 
prospective longitudinal studies. 
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Supplemental Figure 1. Recoding of power Doppler score within 2 mm of the cortex, Figure shown as Supplemental 
Figure 1 in Chapter 2. 
SUPPLEMENTAL DATA
Supplemental Table 1. Participant characteristics
PsA patients age 35-60 
(n=50)
Healthy volunteers age 
35-60 (n=25)
Age, yrs 50 ± 6 47 ± 6
Male 23 (46) 12 (48)
BMI 28 ± 5 25 ± 4**
Disease duration, yrs 7 (4-12)
Fulfilling CASPAR criteria 48 (96)
Swollen joint count (66) 0 (0-2)
Tender joint count (68) 3 (0-8)
LEI 0 (0-2) 0 (0-0)**
MASES 1 (0-2) 0 (0-0)**
PASI* 0.5 (0-1.8)
Regularly exercising 25 (50) 25 (100)**
Avoidance 29 (58) 4 (16)**
Current medication use
NSAID 22 (44) 1 (4)**
DMARD 33 (66) 0 (0)**
Prednisone 24 (48) 0 (0)**
Biological DMARD 40 (48)
Data presented as mean  ± standard deviation, n (%) or median (interquartile range). 
*excluding 1 patient without a history of psoriasis. 
**PsA vs. Healthy volunteers p < 0.01 
PsA: psoriatic arthritis; BMI: body mass index; CASPAR: Classification criteria for psoriatic arthritis; LEI: Leeds enthesitis 
index; MASES: Maastricht ankylosing spondylitis enthesitis score; PASI: psoriasis area and severity index; NSAID: non-
steroidal anti-inflammatory drug; DMARD: disease modifying anti-rheumatic drug.  
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ABSTRACT
Objective: Psoriatic arthritis (PsA) is a multifaceted disease. Affecting joints, skin, entheses 
and dactylitis, its impact on health-related quality of life (HRQOL) could be substantial. We 
aim to assess HRQOL in patients with newly diagnosed PsA and analyze its associations with 
disease manifestations. 
Methods: Data collected at time of diagnosis from patients with PsA included in the Dutch 
southwest Early Psoriatic Arthritis cohoRt (DEPAR) study were used. HRQOL was assessed 
using eight domains of the Short Form-36 (SF-36) questionnaire. Patients were classified 
based on primary manifestation in arthritis subtypes (i.e., mono-, oligo-, or polyarthritis) 
and other subtypes (i.e., enthesitis, dactylitis, and axial disease). In all patients, presence of 
arthritis, enthesitis, dactylitis, psoriasis and chronic inflammatory back pain was determined. 
Multivariable linear regression was used to determine associations of PsA manifestations with 
HRQOL. 
Results: Of 405 patients, primary manifestation was peripheral arthritis in 320 (78 
monoarthritis, 151 oligoarthritis, and 91 polyarthritis), enthesitis in 37, axial disease in 9 and 
dactylitis in 39. Mean scores of SF-36 domains were lower than the Dutch reference population 
and similar across arthritis subtypes. A higher number of enthesitis locations and tender joints, 
and presence of chronic back pain, were independently associated with worse SF-36 scores. 
Psoriasis and dactylitis were not associated with worse scores. 
Conclusion: HRQOL was diminished in PsA at time of diagnosis compared to the Dutch 
reference population, and tender joints, enthesitis at clinical examination, and back pain as 
indicators of pain impacted HRQOL. 
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INTRODUCTION 
Psoriatic arthritis (PsA) is a spondyloarthropathy that can present with arthritis, enthesitis, 
psoriasis, spondylitis and dactylitis.1 PsA patients report lower health-related quality of life 
(HRQOL) than the general population and patients with psoriasis.2-6 The reported burden of 
disease is substantial; however, HRQOL in PsA is studied only in patients with longstanding 
disease. It is unknown to what extent this burden of disease is already present at time of 
diagnosis before starting treatment. Also, very little is known about how much each disease 
manifestation impacts HRQOL. 
 One of the challenges in treating PsA is the heterogeneity of manifestations. In 
studies analyzing the effect of clinical variables on HRQOL in PsA patients, arthritis has 
been the only musculoskeletal manifestation investigated.7, 8 Within PsA patients, arthritis 
was found to impair HRQOL. A study in PsA showed that psoriasis, which is known to affect 
HRQOL, had no additional effect on HRQOL in patients who already had PsA.8 The Corrona 
registry, however, showed that patients with more skin involvement report more pain and 
disability than patients with less skin involvement. In all studies evaluating the effect of PsA 
manifestations on HRQOL, other PsA specific disease features such as dactylitis or enthesitis 
were not specifically evaluated. In making treatment decision, it is very important to know how 
all PsA manifestations affect HRQOL. 
 The main objectives of this real-life cohort study are (1) to describe the quality of life 
in newly diagnosed patients with PsA, and (2) to analyze the influence of swollen and tender 
joints, enthesitis, dactylitis, back complaints and skin involvement on HRQOL.
MATERIALS AND METHODS
Patients and Setting
Newly diagnosed patients with PsA were invited to participate in the Dutch southwest Early 
Psoriatic Arthritis cohoRt (DEPAR). The diagnosis was made by rheumatologists and based on 
expert opinion; no classification criteria were applied, to ensure enrolment of a population 
representative of daily clinical practice. All eligible patients with newly diagnosed PsA (aged 
≥18 years, no current treatment with disease-modifying antirheumatic drugs [DMARDs] for 
joint complaints, and sufficient knowledge of the Dutch language) were asked to participate. 
Use of DMARDs for psoriasis and use of non-steroidal anti-inflammatory drugs were allowed. 
Patients were recruited in centers in the southwest of the Netherlands (1 academic hospital, 
10 general hospitals, and 1 treatment center specialized in rheumatic care). For this analysis, 
baseline data from patients included between August 2013 and November 2016 was used. 
Written informed consent was obtained from all participants according to the Declaration of 
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Helsinki. The study was approved by the local medical research ethics committee of Erasmus 
MC, University Medical Center Rotterdam, the Netherlands (MEC-2012-549).
Patient and disease characteristics
Trained research nurses collected clinical data, including swollen and tender joint count (66 
and 68 joints, respectively), enthesitis at clinical examination (Leeds Enthesitis Index [LEI]9 and 
Maastricht Ankylosing Spondylitis Enthesitis Score [MASES]10), dactylitis (Leeds Dactylitis Index 
[LDI]11), psoriasis (Psoriasis Area and Severity Index [PASI]12), and a standardized history of 
complaints (including duration, musculoskeletal complaints, and back complaints). Psoriasis 
severity was categorized as absent (PASI = 0), mild (PASI > 0 and PASI ≤ 7), and moderate to 
severe (PASI > 7).13 Patients were classified as having chronic back pain (CBP) if they reported 
chronic complaints of back pain for a duration of longer than 3 months at present or in the 
past 12 months, and with onset < 45 years of age. In these patients, fulfilment of Assessment 
of SpondyloArthritis international Society (ASAS) classification criteria for inflammatory back 
pain (IBP) was determined.14 Disease subtype at time of diagnosis was determined by the 
rheumatologist and defined by primary presentation as monoarthritis (1 joint), oligoarthritis 
(2-4 joints) and polyarthritis (≥ 5 joints), and in case of absence of peripheral arthritis defined 
as enthesitis, dactylitis, or with axial involvement. A diagnosis of enthesitis was made based on 
patient-reported complaints of enthesitis and entheseal pain at subsequent clinical assessment 
by the physician. The subtyping was based on the most prominent musculoskeletal feature 
at presentation as assessed by the rheumatologist. Fulfillment of ClASsification criteria for 
Psoriatic ARthritis (CASPAR) was determined.15
Primary outcome of interest - HRQOL
HRQOL was assessed using the Short Form-36 (SF-36). This generic measure covers 8 domains: 
physical functioning (PF), physical role functioning (PR), bodily pain (BP), general health 
(GH), vitality (VI), social functioning (SF), emotional role functioning (ER), and mental health 
(MH). With these separate domains, the physical component summary (PCS) and mental 
component summary (MCS) were calculated to provide a global score.16 The domains have a 
range of 0 to 100 with a higher score representing a better state and were compared to domain 
scores of the Dutch reference population.17 This reference population (n=1742) had a mean 
age of 47.6 years and 56% was male. The component summary scores were adjusted by the 
general Dutch population, resulting in norm-based scores with mean 50 (standard deviation 
[SD] 10). Patients filled out their questionnaires either online (92%) or on paper, shortly before 
or after their visit to the research nurse. 
Statistical analysis 
Patient characteristics were described using simple descriptive analysis techniques. To 
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evaluate the impact of each disease manifestation, domain scores in subgroups of arthritis 
(monoarthritis, oligoarthritis, and polyarthritis), enthesitis (present and absent), psoriasis 
(absent, mild, moderate-severe), dactylitis (present and absent) and back pain (no CBP, CBP-
IBP+, and CBP-IBP-) were compared and differences were tested with Wilcoxon rank tests in case 
of 2 subgroups and Kruskal-Wallis tests in case of more subgroups. In subsequent univariable 
and multivariable linear regression analyses, we tested whether these associations were 
also present when adjusting the scores for the other disease manifestations. The dependent 
variables were the SF-36 PCS and SF-36 MCS. The SF-36 MCS was square-transformed to 
improve model fitting. Independent variables included in both models were age, sex, swollen 
joint count (66), tender joint count (68), number of enthesitis at clinical examination (LEI + 
MASES), presence of dactylitis (LDI>0), PASI, and presence of IBP. Interaction terms of enthesitis 
at clinical examination, tender joint count, and chronic back pain were tested. Complete cases 
were used in these analyses and with a sensitivity analysis the effects of patients with missing 
variables were tested. The variance inflation factor (VIF) was calculated in each model to test 
for multicollinearity. STATA 14.0 was used. 
RESULTS
In November 2016, 405 patients with newly diagnosed PsA had been included. Table 1 shows 
patient characteristics at baseline. Mean age was 50 years (SD 13.8) and 49% was male. Median 
self-reported duration of complaints at time of diagnosis was 11.6 months (interquartile range 
[IQR] 3.9-32 months). The primary manifestation at time of diagnosis was monoarthritis in 78 
patients (19%), oligoarthritis in 151 (37%), and polyarthritis in 91 (22%). Primary manifestation 
was in 37 (9%) enthesitis, 9 (2%) axial disease, and 39 (10%) dactylitis among patients without 
peripheral arthritis. Most patients had more than 1 feature present. In 186 of 404 patients (46%) 
enthesitis at clinical examination was present according to the LEI and/or MASES. Dactylitis 
was present in 51 patients (13%), 344 patients had active psoriasis (85%, median PASI score 
2.6, IQR 1-4.7) and 57 (15%) fulfilled ASAS IBP criteria. The CASPAR criteria were fulfilled by 328 
(81%) patients. Of the 77 that did not fulfill CASPAR criteria, 31 (8%) had a missing rheumatoid 
factor (RF) status, 24 (6%) only had a history or family history of psoriasis combined with 
negative RF, and 9 patients had a moderately positive RF and were negative for anti-cyclic 
citrullinated protein antibody. 
 The 62 (16%) patients with missing baseline questionnaires were not significantly 
different from the other patients (Supplemental Table 1). Overall, HRQOL was lower in patients 
with early PsA than in the Dutch reference population. The differences were greater in the 
physical domains (i.e. PF, PR, BP, and GH) while psychosocial domains (i.e. VI, SF, ER, and MH) 
were close to the healthy population (Figure 1A). SF-36 scores did not differ significantly among 
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Table 1. Patient characteristics of DEPAR cohort (n=405) 
Characteristics Values
Demographic characteristics  
Age, mean (SD) 50.1 (13.8)
Male, n (%) 200 (49)
Duration of complaints, months, median (IQR) 11.6 (3.9-32)
Paid employment, n (%) 216 (63)
CASPAR criteria$, n (%) 328 (81)
Clinical characteristics  
BMI, mean (SD) 28.1 (5.2)
Tender joint count (68), median (IQR) 3 (1-7)
Swollen joint count (66), median (IQR) 2 (1-4)
Disease subtype, n (%)
Monoarthritis 78 (19)
Oligoarthritis 151 (37)
Polyarthritis 91 (22)
Enthesitis 37 (9)
    Axial Disease 9 (2)
    Dactylitis 39 (10)
Enthesitis at clinical examination
LEI > 0, n (%) 162 (40)
LEI in case of enthesitis, median (IQR) 2 (1-3)
MASES > 0, n (%) 136 (34)
MASES in case of enthesitis, median (IQR) 2 (1-3)
Dactylitis present, n (%) 51 (13)
Psoriasis
PASI > 0, n (%) 344 (85)
PASI in case of psoriasis, median (IQR) 2.6 (1-4.7)
Family history of psoriasis in case of no active psoriasis, n (%) 36 (60)
CBP onset < 45 years of age* 147 (39)
Fulfillment of IBP criteria in CBP* 57 (15)
$Rheumatoid Factor status missing in 31 (8%), and 24 (6%) only history or family history of psoriasis with negative 
rheumatoid factor. 
*Data on CBP in 380 patients. 
DEPAR: Dutch southwest Early Psoriatic Arthritis cohoRt; SD: Standard Deviation; IQR: interquartile range; CASPAR: 
Classification criteria for Psoriatic Arthritis; BMI: body mass index; LEI: Leeds Enthesitis Index; MASES: Maastricht 
Ankylosing Spondylitis Enthesitis Index; PASI: Psoriasis Area and Severity Index; CBP: chronic back pain, defined as 
presence of back pain complaints for more than 3 months at present or in the past 12 months; IBP: inflammatory back 
pain (criteria: ASAS criteria for IBP); ASAS: Assessment of SpondyloArthritis international Society. 
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Figure 1. SF-36 domain scores in subgroups
Health-related quality of life measured these domains of the SF-36: physical functioning (PF), physical role functioning 
(PR), bodily pain (BP), general health (GH), vitality (VI), social functioning (SF), emotional role functioning (ER), and 
mental health (MH) (SF-36).
A: All patients
B: Arthritis subgroups
C: Enthesitis subgroups (LEI and/or MASES ≥ 0)
D: Dactylitis subgroups (LDI ≥ 0)
E: Psoriasis subgroups (PASI: none 0, mild 0-7, moderate/severe >7)
F: Back pain (no CBP with onset before 45 yrs, or CBP with or without IBP) 
PsA: psoriatic arthritis; SF-36: Short Form-36; LEI: Leeds Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis 
Enthesitis Score; LDI: Leeds Dactylitis Index; PASI: Psoriasis Area and Severity Index; CBP: chronic back pain; IBP: 
inflammatory back pain.  
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patients with monoarthritis, oligoarthritis, or polyarthritis (Figure 1B, and Supplemental Table 
2). Patients with enthesitis at clinical examination had significantly lower scores on all SF-36 
domains than patients without enthesitis at clinical examination (Figure 1C, and Supplemental 
Table 3). Severity of psoriasis and presence of dactylitis did not significantly influence SF-36 
scores (Figure 1D and Figure 1E, and Supplemental Table 4 and 5). Patients reporting CBP 
with onset before 45 years of age had significantly worse HRQOL in all domains of the SF-36 
than those without. There was no significant difference in HRQOL between patients with CBP 
fulfilling ASAS IBP criteria and those not fulfilling ASAS IBP criteria, except for the MH domain, 
which is worse in patients fulfilling ASAS IBP criteria (Figure 1 F, Supplemental Table 6). Patients 
with enthesitis at clinical examination also reported IBP more often. 
Table 2. Univariable and multivariable linear regression analysis of SF-36 PCS
Univariable Multivariable
Variables β (95% CI) β (95% CI)
Age, yrs -0.06 (-0.13;0.01) -0.05 (-0.12;0.01)
Sex (male vs female) -3.69 (-5.51;-1.86) -2.39 (-4.24;-0.55)
Swollen joint count (66) -0.28 (-0.55;-0.01) -0.07 (-0.37;0.23)
Tender joint count (68) -0.43 (-0.59;-0.26) -0.25 (-0.44;-0.05)
No. enthesitis locations -1.11 (-1.47;-0.74) -0.84 (-1.25;-0.43)
Dactylitis (no vs yes) -0.37 (-3.22;2.49) -0.97 (-3.63;1.69)
PASI -0.13 (-0.39;0.12) -0.12 (-0.36;0.11)
Chronic back pain (no vs yes) -2.71 (-5.31;-0.11) -5.33 (-9.56;-1.1)
Enthesitis x chronic back pain -2.45 (-5.48;0.58) 5.43 (0.38;10.48)
Analysis of complete cases (n=311), significant coefficients in bold face. 
SF-36 PCS: Short Form-36 physical component summary; PASI: Psoriasis Area and Severity Index; CI: confidence 
interval. 
Table 3. Univariable and Multivariable linear regression analysis of SF36-MCS (square transformation)
Univariable Multivariable
Variables β (95% CI) β (95% CI)
Age, yrs 1.97 (-5.50;9.44) 1.3 (-6.03;8.63)
Sex (male vs female) -432 (-632;-231) -292 (-499;-85)
Swollen joint count (66) 5 (-25;35) 27 (-6;61)
Tender joint count (68) -40 (-59;-22) -38 (-59;-16)
No. enthesitis locations -93 (-134;-52) -38 (-83;7)
Dactylitis (no vs yes) 118 (-197;433) 104 (-195;402)
PASI -15 (-43;13) -16 (-43;10)
Chronic back pain (no vs yes) -660 (-987;-333) -298 (-580;-16)
Analysis of complete cases (n=317), significant coefficients in bold face. 
MCS square-transformed for a better distribution. SF-36 MCS: Short Form-36 mental component summary; PASI: 
Psoriasis Area and Severity Index; CI: confidence interval. 
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 To test the independent association between disease manifestations and HRQOL, 
univariable and multivariable linear regression analyses of the PCS and MCS were conducted 
(Table 2 and Table 3). In the univariable analysis, female sex, more tender joints, more 
enthesitis at clinical examination, and chronic back pain were associated with worse PCS 
and MCS scores. These factors remained significant in the multivariable analysis of the PCS. 
In the analysis of the MCS, the interaction term of enthesitis and CBP was not significant and 
removed from the final model. In the final multivariable model of the MCS, female sex and 
tender joint count were independently associated with worse MCS scores. In the sensitivity 
analysis of missing data, no relevant changes of βs and p-values occurred. 
DISCUSSION
The main objective of this study was to describe HRQOL in PsA at time of diagnosis. Compared 
to the Dutch reference population, HRQOL was lower in patients with PsA and especially lower 
in the physical domains of the SF-36. Lower levels of HRQOL were observed in patients with 
more tender joints, more locations of enthesitis at clinical examinations, and patients with CBP. 
Because patients often presented with more than 1 disease manifestation, the contribution 
of each manifestation was evaluated in a multivariable analysis. Tender joints, enthesitis at 
clinical examination, and CBP were all independently associated with worse HRQOL. Psoriasis 
and presence of dactylitis did not result in loss of HRQOL as measured by the SF-36.
 To our knowledge, no other studies have assessed HRQOL in a stage of disease this 
early. Husted et al. reported HRQOL of 631 established PsA patients with moderate to severe 
disease activity, and also showed that PsA lowers HRQOL.7 Similar results were seen in a study 
of 551 veterans with PsA.18 Many clinical trials, however, report a higher disease activity and 
a lower HRQOL before starting treatment than we found.19-22 These data cannot directly be 
compared to our data, because the populations probably differ in terms of disease severity 
and selection of patients. It does, however, indicate that PsA is a severe chronic disease that 
already affects HRQOL at time of diagnosis, though the effect of disease in this usual-care 
population is not as great as in patients in which the first disease-modifying treatment did not 
suffice. 
 Within the PsA population, presence of tender joints, enthesitis at clinical examination, 
and CBP were associated with worse HRQOL, which shows that pain as a consequence of 
inflammation is an important determinant of HRQOL. Entheseal tenderness at clinical 
examination reflecting enthesitis is 1 of the sources of pain identified. It worsens HRQOL, even 
in patients who already have a polyarthritis. The relationship between enthesitis and HRQOL 
has not been investigated in PsA specifically, but some work has been done in other patients 
with spondyloarthritis (SpA). A study of 1505 patients with SpA, of whom 18% had PsA, showed 
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that patients with enthesitis at clinical examination reported lower disease-specific HRQOL.23 
Other studies in axial SpA found strong correlations between the total enthesitis score and 
lower scores on physical subscales of the SF-36.24-26 No specific analysis in PsA was done. 
These and our findings suggest specific attention for enthesitis is needed in the treatment for 
PsA. 
 The validity of measuring enthesitis at clinical examination could be debated. 
Although joints are assessed for the presence of swelling and pain to detect arthritis, 
enthesitis does often not present with clearly visible signs of inflammation but with pain 
only. However, entheseal pain does not necessarily equal enthesitis; it could be caused by 
other enthesiopathies such as degenerative or metabolic processes.27 Most cases of entheseal 
pain in PsA do seem to have an inflammatory origin, as it is known to resolve after biological 
treatment.28, 29 But in a small part of the patients, it may indicate a more general pain syndrome. 
In our study, patient generally reported enthesitis at only 1 to 3 locations, which is less likely in 
case of a general pain syndrome. 
 Psoriasis, present in 85% of patients, was usually mild and its influence on HRQOL 
was not detected with the SF-36. This may suggest psoriasis does not affect HRQOL in PsA. In 
studies comparing HRQOL in PsA and rheumatoid arthritis, emotional and mental health were 
more affected in PsA than in rheumatoid arthritis2, 30, 31 and this difference was attributed to the 
presence of psoriasis in PsA patients. In patients with PsA, we did not see an effect of psoriasis 
on HRQOL, possibly because at time of diagnosis pain overshadowed skin involvement in its 
association with HRQOL. In addition, the effect of psoriasis symptoms such as itching and skin 
pain might not be detected in a general health questionnaire and may require Dermatology 
Life Quality Index or Skindex. 
 There are several strengths and limitations to this study. One of the strengths is that 
this study has a large population of patients with PsA, which makes it possible to analyze the 
disease in different subgroups of patients. In addition, patients with a new PsA diagnosis made 
by the rheumatologist were all eligible to participate if they had not yet received treatment for 
PsA. Our incident PsA cohort therefore reflects the population as seen in usual clinical practice, 
not influenced by classification criteria or criteria from trials. We were able to relate the burden 
of disease to the general population and compare patients with different manifestations 
by using the SF-36. However, by using this general questionnaire we possibly missed the 
disease-specific impact on HRQOL. With the data available, we were not able to distinguish 
CBP with inflammatory origin from lower back complaints commonly occurring in the general 
population.32 Nevertheless, because the presence of CBP affects functioning, it is a sign that 
pain warrants attention in the treatment of PsA. Last, we only performed a cross-sectional 
analysis of HRQOL. Further evaluation is needed of the evolvement of manifestations and 
subsequent change in HRQOL over time. 
 We found that HRQOL was diminished in PsA at time of diagnosis compared with the 
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Dutch reference population and showed that tender joints, enthesitis at clinical examination, 
and presence of CBP impacted HRQOL. Pain is an important determinant of functioning in 
early disease, which warrants attention in the treatment of PsA.
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SUPPLEMENTAL DATA
In order to provide extra insight in the data besides visual representation from the figures in 
the manuscript, we added Supplemental Table 2-6 and performed non-parametric tests on 
all groups.
Supplemental Table 1. Demographic characteristics of patients with non-missing and missing questionnaires
Non-missing 
questionnaires (n=341)
Missing 
questionnaires (n=64) p-value
Demographic characteristics
Age, mean (SD) 50 (14) 48 (14) 0.24
Male, n (%) 173 (51) 27 (42) 0.21
Duration of complaints, median months (IQR) 11.7 (4-34) 11.1 (3.5-26) 0.93
Clinical characteristics    
BMI, mean (SD) 28 (5) 28 (5) 0.37
Tender joint count (68), median (IQR) 3 (1-7) 3 (2-8.5) 0.05
Swollen joint count (66), median (IQR) 2 (1-4) 2 (1-4.5) 0.28
Disease subtype, n (%)
Monoarthritis 65 (19) 14 (22)
Oligoarthritis 128 (38) 23 (36)
Polyarthritis 76 (22) 15 (23)
Enthesitis 31 (9) 6 (9)
Axial Disease 8 (2) 1 (2)
Dactylitis 34 (10) 5 (8)
Enthesitis
LEI > 0, n (%) 119 (35) 17 (27) 0.19
LEI in case of enthesitis, median (IQR) 2 (1-3) 2 (1-3) 0.82
MASES > 0, n (%) 119 (35) 17 (27) 0.19
MASES in case of enthesitis, median (IQR) 2 (1-3) 2 (1-3) 0.27
Dactylitis present, n (%) 43 (13) 8 (13) 0.98
Psoriasis
PASI > 0, n (%) 291 (86) 53 (83) 0.57
PASI in case of psoriasis, median (IQR) 2.6 (1-4.7) 2.5 (1-4.5) 0.85
CBP onset < 45 years of age 118 (37) 29 (47) 0.15
Fulfillment of IBP criteria in CBP 47 (42) 10 (36) 0.54
SD: Standard Deviation; IQR: interquartile range; BMI: body mass index; LEI: Leeds Enthesitis Index; MASES: Maastricht 
Ankylosing Spondylitis Enthesitis Index; PASI: Psoriasis Area and Severity Index; CBP: chronic back pain, defined as 
presence of back pain complaints for more than 3 months at present or in the past 12 months; IBP: inflammatory back 
pain (criteria: ASAS criteria for IBP); ASAS: Assessment of SpondyloArthritis international Society. 
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Supplemental Table 2. SF-36 Domain scores in arthritis subgroups
Monoarthritis 
(n=64)
Oligoarthritis 
(n=128)
Polyarthritis 
(n=77)
Physical Functioning (PF) 70 (45-85) 65 (45-80) 65 (40-80)
Physical Role Functioning (PR) 56 (38-75) 50 (25-75) 50 (25-63)
Bodily Pain (BP) 51 (41-62) 51 (32-62) 41 (31-62)
General Health (GH) 52 (44-67) 57 (40-72) 52 (37-67)
Vitality (VI) 56 (44-72) 56 (38-69) 50 (38-69)
Social Functioning (SF) 75 (56-88) 75 (50-100) 75 (50-88)
Emotional Role Functioning (ER) 83 (50-100) 75 (50-100) 75 (50-100)
Mental Health (MH) 75 (60-85) 75 (60-85) 70 (55-80)
Data shown as median (interquartile range). 
Kruskal-Wallis tests comparing overall scores between subgroups, none significant.
Supplemental Table 3. SF-36 Domain scores in enthesitis subgroups
Enthesitis - 
(n=184)
Enthesitis + 
(n=157)
Physical Functioning (PF) 75 (55-90) 58 (35-75)*
Physical Role Functioning (PR) 63 (38-84) 50 (25-63)*
Bodily Pain (BP) 51 (41-62) 41 (31-51)*
General Health (GH) 62 (45-72) 47 (35-57)*
Vitality (VI) 63 (44-75) 44 (31-56)*
Social Functioning (SF) 88 (63-100) 63 (50-88)*
Emotional Role Functioning (ER) 100 (58-100) 67 (50-100)*
Mental Health (MH) 80 (65-90) 65 (50-75)*
Data shown as median (interquartile range).
*p < 0.05 Wilcoxon rank tests.
Supplemental Table 4. SF-36 Domain scores in psoriasis subgroups
No Psoriasis 
(n=50)
Mild Psoriasis 
(n=250)
Moderate/Severe 
Psoriasis (n=42)
Physical Functioning (PF) 65 (45-75) 68 (45-85) 63 (40-80)
Physical Role Functioning (PR) 50 (25-63) 50 (31-75) 50 (25-63)
Bodily Pain (BP) 51 (31-62) 51 (41-62) 41 (31-62)*
General Health (GH) 55 (42-67) 55 (40-67) 52 (35-67)
Vitality (VI) 47 (38-63) 56 (38-69) 56 (38-63)
Social Functioning (SF) 75 (50-100) 75 (50-100) 75 (50-88)
Emotional Role Functioning (ER) 83 (50-100) 75 (50-100) 75 (50-83)
Mental Health (MH) 73 (60-85) 75 (60-85) 73 (55-80)
Data shown as median (interquartile range).
*p < 0.05 Kruskal-Wallis tests comparing overall scores between subgroups.
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Supplemental Table 5. SF-36 Domain scores in dactylitis subgroups
Dactylitis - 
(n=278)
Dactylitis + 
(n=31)
Physical Functioning (PF) 65 (45-80) 70 (50-85)
Physical Role Functioning (PR) 50 (31-75) 56 (25-69)
Bodily Pain (BP) 51 (32-62) 41 (41-62)
General Health (GH) 52 (40-67) 62 (40-67)
Vitality (VI) 56 (38-69) 56 (44-69)
Social Functioning (SF) 75 (50-100) 75 (63-100)
Emotional Role Functioning (ER) 75 (50-100) 75 (58-100)
Mental Health (MH) 75 (56-85) 75 (65-90)
Data shown as median (interquartile range). 
Wilcoxon rank test, none significant.
Supplemental Table 6. SF-36 Domain scores in chronic back pain subgroups
no CBP 
(n=200)
CBP, IBP negative 
(n=66)
CBP, IBP positive 
(n=47)
Physical Functioning (PF) 70 (50-85)* 58 (30-75) 55 (40-75)
Physical Role Functioning (PR) 56 (41-81)* 44 (25-63) 50 (31-63)
Bodily Pain (BP) 51 (41-62)* 41 (31-61) 41 (31-62)
General Health (GH) 57 (44-72)* 47 (35-62) 45 (35-62)
Vitality (VI) 56 (44-75)* 50 (38-63) 38 (25-56)
Social Functioning (SF) 75 (63-100)* 63 (50-88) 63 (50-88)
Emotional Role Functioning (ER) 75 (58-100)* 67 (42-100) 75 (50-100)
Mental Health (MH) 75 (60-85)* 75 (55-85) 65 (50-80)#
Data shown as median (interquartile range). 
*p < 0.05 Wilcoxon rank test comparing domain scores in no CBP onset < 45 yrs vs CBP onset < 45 yrs
#p < 0.05 Wilcoxon rank test comparing scores on domains within CBP, IBP fulfillment vs no IBP fulfillment 
CBP: chronic back pain; IBP: inflammatory back pain (criteria: ASAS criteria for IBP); ASAS: Assessment of 
SpondyloArthritis international Society. 
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ABSTRACT
Background: In a cohort of patients with newly diagnosed psoriatic arthritis (PsA) who 
received usual care, we investigated the impact of time elapsed to minimal disease activity 
(MDA) on health-related quality of life (HRQOL), work productivity, and radiographic damage 
throughout the first year after diagnosis.
Methods: Data collected in the Dutch southwest early PsA cohort (DEPAR) study were analyzed. 
These 3-monthly data encompassed disease activity, HRQOL measured with the Short Form-
36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary; and 
productivity with the Productivity Cost Questionnaire. Radiographic damage was scored at 
baseline and at 12 months with the PsA-modified Sharp/van der Heijde score. Patients were 
classified by time to MDA as  in early (within 3 months), late (at 6-12 months), and never MDA 
in the first year. 
Results: We included  296 patients who had had their 1-year outpatient visit (mean age 51 
years, 53% male). Ninety-six (32%) were classified as early MDA, 78 (26%) as late MDA, and 98 
(33%) as never MDA. Data of 24 patients (8%) were missing. SF-36 PCS and productivity scores 
improved after gaining MDA, but remained low in never MDA patients. At 1 year, SF-36 PCS and 
productivity scores were similar in early and late MDA patients. Radiographic progression rate 
was low and similar in all groups. 
Conclusion: Gaining MDA was associated with considerable improvement in HRQoL and 
functioning, irrespective of time to first MDA. In the one third of patients not in MDA in the first 
year, the disease had a substantial health impact. 
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory disease presenting with arthritis, enthesitis, 
spondylitis, dactylitis, and psoriasis.1 As in other rheumatic diseases, chronic inflammation 
leads to progressive joint damage, increased disability and reduced life expectancy.2-4 Treatment 
with disease-modifying antirheumatic drugs (DMARDs) can alleviate this inflammation and 
prevent these complications.5, 6 Better clinical, functional, and structural outcomes have 
been achieved with the use of treat-to-target strategies in patients with rheumatoid arthritis.7 
This implies that treatment is intensified until a target of low disease activity is reached. This 
strategy has been recommended in the treatment of PsA as well,8 although as yet there is 
no consensus of which target to use. Minimal disease activity (MDA) is one of the proposed 
treatment targets in PsA.
 MDA is assumed to have been reached when  at least 5 out of 7 PsA remission criteria 
are met.9 In previous cross-sectional studies, a state of MDA was strongly related with better 
functioning and health-related quality of life (HRQOL).10-12 Longitudinal studies confirming 
these findings are lacking. We need more information on how the state of MDA is related to 
long-term improvement in disability and whether achieving MDA early after the diagnosis 
results in better outcomes than achieving MDA at a later stage. We investigated the impact 
of time elapsed from diagnosis to MDA on HRQOL, productivity and radiographic damage at 
1-year follow up in a cohort of patients newly diagnosed with PsA and receiving usual care. We 
established if patients had reached MDA early, late or never in the first year after diagnosis and 
how their HRQOL, work productivity and radiographic damage was throughout the first year 
after diagnosis. 
METHODS
Patients and setting
We used data collected in the Dutch southwest Early Psoriatic Arthritis cohoRt (DEPAR) study, 
of which details are described elsewhere.11 Patients with a new diagnosis of PsA are eligible 
to participate if they have not yet received treatment with DMARDs for PsA. Written informed 
consent was obtained from all participants according to the Declaration of Helsinki. The study 
was approved by the medical research ethics committee of the Erasmus University Medical 
Center Rotterdam, the Netherlands (MEC-2012-549). We analyzed data collected between 
August 2013 and June 2017 and excluded patients with baseline visits after June 2016. 
Data collection
In the first year, data are collected every 3 months. During the study visits, trained research 
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nurses collect clinical data, including swollen and tender joint count (resp. SJC 66 and TJC 
68 joints), enthesitis at clinical examination (Leeds Enthesitis Index [LEI]13), and psoriasis 
(Psoriasis Area and Severity Index [PASI]14). Patients complete multiple questionnaires shortly 
before or after their visits. For this analysis we used data on the Short Form-36 (SF-3615); the 
Health Assessment Questionnaire (HAQ16); the Productivity Cost Questionnaire(PCQ17), and 
patient-reported Visual Analogue Scale (VAS) scores for global and pain. 
Minimal Disease Activity 
MDA state was determined at each visit within the first year. A state of MDA was assumed to 
have been reached if 5 of 7 MDA criteria were met: SJC ≤ 1, TJC ≤ 1, LEI ≤ 1, PASI ≤ 1, global VAS 
≤ 20 mm, pain VAS ≤ 15 mm, HAQ ≤ 0.5.9 In case of missing data of some criteria, MDA status 
was ascertained irrespective of the missing information (e.g. fulfilling 5 criteria and missing 2 
criteria). If missing information could alter the MDA status (e.g. fulfilling 4 criteria and missing 2) 
we considered MDA status missing. If MDA status before and after a missing visit was equal (i.e. 
both MDA or both no MDA), we assumed that MDA status at the missing visit was equal to that 
state. Achieving MDA was classified as early if it had been achieved at baseline or at 3 months; 
as late if it was first achieved after 3 months but within the first year; and as never if it was not 
achieved in the first year. In addition, achieving MDA was classified as sustained if patients 
remained in MDA until their 1-year follow up visit. 
Outcomes
Patients self-reported HRQOL with the SF-36 Physical Component Summary (PCS) and Mental 
Component Summary (MCS). Work productivity was assessed with the PCQ, relating to work 
and productivity in the 4 weeks preceding the study visit. We determined employment status, 
absence, working hours, and productivity loss at work and at home throughout the first year. 
The actual number of productivity hours per week was calculated by subtracting hours of 
absence and productivity loss at work in hours from the total number of self-reported working 
hours. 
 Radiographs of the hand and feet obtained at baseline and after 1 year were scored 
twice, by 3 trained assessors separately. The assessors were blinded to the patient’s identity 
and clinical data and scored the images in chronological order. According to the PsA-modified 
Sharp/Van der Heijde score (PsA-SHS), erosions and narrowing of hand and feet joints were 
scored with a maximum of 320 for erosions and 208 for joint space narrowing.18 Differences 
in absolute score above 2 and differences in progression were discussed by the 2 assessors. 
Regarding the inter-rater reliability, the kappa statistics was 0.79 with absolute agreement of 
99%. For each patient the mean of 2 scores was calculated. The smallest detectable difference 
(SDD) was 0.27. Progression was defined as an mean increase in PsA-SHS in the first year 
exceeding the SDD. 
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Statistical analysis
Differences in characteristics between MDA groups were tested with ANOVA tests and 
subsequent t-tests for continuous data and chi-squared tests for categorical data. The effect 
of time to MDA on outcomes after 1 year was analyzed with multiple linear regression analysis 
with outcomes SF-36 PCS, SF-36 MCS and productivity. The association of time to MDA (early 
vs. late, early vs. never and late vs. never) with the outcome was corrected for baseline SF-36 or 
productivity score, age, gender, symptom duration, DMARDs use, erosive disease at baseline, 
and baseline disease activity (baseline SJC, TJC, LEI, PASI, VAS global, VAS pain and HAQ). In 
the subset of patients using DMARDs in the first year, the same analysis was performed with 
the added variables time to start and duration of DMARD therapy. Linear mixed effects models 
were used to compare progression of outcomes between the 3 groups and to account for 
missing data. Baseline outcome score, baseline disease activity and erosive disease, age, 
gender, symptom duration, DMARD use, time, MDA group and interaction between time and 
MDA group were included in the fixed-effects part. Random intercepts were included in the 
random-effects part; an optimal random-effects structure was chosen based on the Akaike 
information criterion. Analyses were performed in STATA 15.1 and R-3.4.2. 
RESULTS
In July 2017, 296 patients had had their 1-year visit and 268 (92%) could be assigned an MDA 
category. The mean age of the latter was 51.2 years (standard deviation (SD) 14), 142 were male 
(53%) and the median self-reported symptom duration was 1.0 years (interquartile range (IQR) 
0.4-2.7, Table 1). Ninety-four (35%) had achieved MDA within 3 months (early MDA; 40 already 
in MDA at baseline), 77 (29%) between 6 and 12 months (late MDA), and 97 (36%) were never 
in MDA during the first year (never MDA). MDA state was sustained until 1 year by 43 (48%) early 
MDA patients and 46 (52%) late MDA patients. Patients early in MDA were significantly more 
often in MDA than patients late in MDA (of 5 visits: mean 3.6 vs. 1.8, p < 0.01).  
 Age, gender and symptom duration did not differ significantly between groups (Table 
1). Patients never in MDA had significantly higher SJC, TJC, LEI, HAQ, PASI and VAS scores at 
baseline than patients in MDA (both early and late). Patients late in MDA had significantly 
higher disease activity than patients early in MDA on all domains but SJC and PASI. In the first 
year, DMARDs were prescribed to 210 patients (78%): methotrexate to 197 patients (74%) and 
biological therapy to 33 patients (12%). 
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Quality of Life
The evolvement of the mean SF-36 PCS and SF-36 MCS scores per group is shown in Figure 1. 
The mean SF36-PSC score at 1 year was similar in the early and late MDA groups and was better 
than that in the never MDA group. Linear regression analysis of the SF-36 PCS score at 1 year, 
correcting for baseline score, gender, age, symptom duration, DMARD use, erosive disease 
at baseline, and baseline disease activity, showed that SF-36 PSC scores were significantly 
lower in the never MDA group than in the early MDA group (β -6.22, 95% CI -9.92, -2.51) and 
the late MDA group (β-7.86, 95% CI -11.52, -4.21, Table 2). At baseline, SF-36 PCS scores in the 
early MDA group were higher than those in the late MDA group and the never MDA group and 
had increased earlier than in the late MDA group. Linear mixed model analysis confirmed a 
difference in evolution over time between the 3 groups (likelihood ratio test (LRT) of interaction 
Table 1. Patient characteristics of MDA groups and of total study population
Early MDA (n= 94) Late MDA (n=77) Never MDA (n=97)
Age 50.1 ± 14 50.4 ± 13 52.8 ± 14
Male 57 (61) 41 (53) 44 (45)
Symptom duration in years 0.9 (0.2-2.4) 0.8 (0.3-1.5) 1.6 (0.4-4.1)
Disease Activity at baseline    
Swollen joint count (66) 1 (1-3) 3 (1-4) 2 (0-6)$
Tender joint count (68) 1 (0-3) 3 (2-7)* 5 (3-12)$
LEI 0 (0-0) 0 (0-1)* 1 (0-2)$
HAQ 0.13 (0.00-0.63) 0.63 (0.38-0.89)* 0.88 (0.63-1.38)$
PASI 1.5 (0.4-3.8) 2.3 (0.3-4.1) 3 (1.2-6.1)$
VAS Global 21 (9-37) 46 (24-66)* 55 (40-70)$
VAS Pain 17 (9-44) 47 (30-63)* 56 (44-74)$
Medication in first year    
Any DMARD 62 (66) 63 (82)* 85 (88)$
Methotrexate 57 (61) 61 (79)* 79 (81)$
Sulfasalazine 8 (9) 14 (18) 23 (24)$
Hydroxychloroquine 4 (4) 11 (14) 8 (8)
Leflunomide 8 (9) 8 (10) 17 (18)
Prednisone (oral) 13 (14) 14 (18) 18 (19)
Prednisone (intramuscular injection) 11 (12) 21 (27)* 34 (35)$
Prednisone (intra-articular injection) 29 (31) 27 (35) 15 (15)$
Biological 5 (5) 12 (16)* 16 (16)
Results shown as mean ± standard deviation, n (%) or median (interquartile range). 
*Early vs Late MDA  
$MDA vs Never MDA p < 0.05 of t-test (continuous data) or chi-squared test (categorical data). 
MDA: Minimal Disease Activity; Early MDA: MDA within 3 months; Late MDA: MDA between 3 and 12 months; Never MDA: 
no MDA within the first year. LEI: Leeds Enthesitis Index; HAQ: Health Assessment Questionnaire; PASI: Psoriasis Area 
and Severity Index; VAS: Visual Analogue Scale; DMARD: disease-modifying antirheumatic drug.
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between time and group: 34.5, p < 0.0001). Results in the subgroup of patients using DMARDs 
were similar in analyses correcting for duration of DMARD therapy and time to start DMARD 
therapy. The SF-36 MCS scores significantly differed between the 3 groups at baseline and 
remained fairly stable over time, which was confirmed by a non-significant interaction term of 
time and MDA in the linear mixed model analysis (LRT 1.73, p=0.42). At 1 year, the SF-36 MCS 
scores were significantly higher in the early MDA group than in the never MDA group (β -6.11, 
95% CI -9.51, -2.70, Table 2). 
Table 2. Linear regression models outcomes after 1 year of MDA groups
β (95% CI)
SF-36 PCS
Early vs Late MDA 1.64 (-1.63; 4.91)
Early vs Never MDA -6.22 (-9.92; -2.51)
Late vs Never MDA -7.86 (-11.52; -4.21)
SF-36 MCS
Early vs Late MDA -2.83 (-6.14; 0.06)
Early vs Never MDA -6.11 (-9.51; -2.70) 
Late vs Never MDA -3.07 (-6.16; 0.02)
Hours productivity loss
Early vs Late MDA 0.78 (-5.63; 7.20)
Early vs Never MDA -6.59 (-14.55; 1.37)
Late vs Never MDA -7.38 (-14.38; -0.38)
All analyses corrected for baseline score, gender, age, symptom duration, use of disease-modifying antirheumatic 
drugs, erosive disease at baseline, and baseline disease activity (SJC66, TJC68, LEI, PASI, VAS global, VAS pain and 
HAQ). 
Early MDA: MDA within 3 months; Late MDA: MDA between 3 and 12 months; Never MDA: no MDA within the first year. 
SF-36: Short Form-36; PCS: Physical Component Summary; MCS: Mental Component Summary. 
Productivity
At 1 year, 207 of the 250 patients who had completed productivity questionnaires (83%) were 
in the employable age. Of those, 153 (74%) were actually employed: 64 (87%) early MDA, 48 
(76%) late MDA and 41 (60%) never MDA patients (Table 3). Of the 53 unemployed subjects, 
7 patients had become unemployed since diagnosis (1 early MDA, 3 late MDA and 3 never 
MDA), and 46 were already unemployed at baseline. At 1 year, 8 reported long-term sick leave 
(1 late MDA [2%] and 7 never MDA [17%]) and 21 short-term sick leave in the past 4 weeks (10 
early MDA [16%], 5 late MDA [11%] and 6 never MDA [18%]). Work productivity loss in the past 
4 weeks was reported most often by never MDA patients (71%, vs early MDA 27% and late MDA 
30%). The  mean productivity loss in patients with productivity loss did not differ significantly 
between the groups. Mean productivity at work of employed patients during the first year is 
shown in Figure 1. Productivity increased in the late MDA group from a baseline level similar 
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to that in the never MDA group, to a level similar to that in the early MDA group at 1-year follow 
up. This was confirmed in the linear regression analysis (Table 2): total productivity at work was 
significantly lower at 1 year in the never MDA group than in the late MDA group (β -7.38 , 95% 
CI -14.38, -0.38). The difference in evolution over time between the 3 groups was confirmed 
in a linear mixed model analysis (LRT of interaction between time and group 6.93, p = 0.032). 
Radiological damage
Mean PsA-SHS was 3.5 (SD 10; 16 missing) at baseline: the erosion score was 1.4 (SD 4.6) and 
the narrowing score was 2.2 (SD 5.9). Mean progression in 1 year was 0.38 (SD 1.4; 31 missing). 
Both baseline and progression scores did not differ significantly between the groups. The  PsA-
SHS score had progressed in 34 patients (14%): 8 in the early MDA group (10%), 11 in the late 
MDA group (17%) and 15 in the never MDA group (17%). Twenty-seven of the 34 patients with 
progression in the first year had already radiological damage at baseline. 
DISCUSSION
In this cohort of newly diagnosed PsA patients receiving usual care, HRQOL and productivity 
throughout the first year after diagnosis were best in those who reached MDA early. At 1 year, 
however, patients late in MDA had achieved similar levels of HRQOL and work productivity as 
patients in the early MDA group, even though they were significantly shorter in MDA. Patients 
never in MDA had significantly lower scores throughout the first year and this remained so at 
their 1-year visit. Radiological progression did not differ in the first year between the 3 groups. 
 In a previous cross-sectional analysis in our cohort, having reached a state of MDA was 
Table 3. Productivity outcomes after 1 year in MDA groups and in total study population
Early MDA (n= 91) Late MDA (n=73) Never MDA (n=86)
Employable age 74 (81) 64 (88) 69 (80)
Employed 64 (87) 48 (76) 41 (60)
Working hours per week 36 (33-39) 35 (31-38) 32 (28-37)
Long-term absence 0 (0) 1 (2) 7 (17)
Short-term absence 10 (16) 5 (11) 6 (18)
Productivity loss at work 17 (27) 14 (30) 24 (71)
Hours per week productivity loss at work 
in patients with productivity loss
6.7 (4-10.5) 7.6 (4.8-16.8) 7.9 (4.5-18.9)
Total productivity at work 32 (29-35) 29 (25-34) 19 (14-25)
Results shown as mean (95% confidence interval) or n (%). 
Early MDA: MDA within 3 months; Late MDA: MDA between 3 and 12; Never MDA: no MDA within first year. Total 
productivity = hours per week - absence - productivity loss at work, calculated in average per week over past 4 weeks. 
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related to better HRQOL and functioning.11 Other studies found similar results.10, 12 The present 
study, however, is the first to address associations between gaining MDA and improvement of 
HRQOL and functioning over time. We found that gaining MDA, irrespective of the time elapsed 
since diagnosis, was associated with subsequent improvements of HRQOL and functioning 
over time. A slightly longer period of high disease activity was not associated with irreversible 
effects on HRQOL, functioning or radiology after 1 year. 
 Still, one third of all patients was not able to achieve MDA in the first year, and also 
did not show improvement in HRQOL and functioning. Even after correcting for baseline 
differences in disease activity and HRQOL scores, these patients’ SF-36 PCS scores were 8 
points lower than in the rest of the population. While patients in the late MDA group showed 
a clinically important improvement,19 patients in the never MDA group did not. Furthermore, 
almost all patients in the latter group reported some form of impact on their work: becoming 
unemployed, sick leave or significant productivity loss at work. Thus, the impact of disease is 
severe and widespread in patients who do not achieve MDA. Interestingly, the baseline values 
of patients in the never MDA group did not differ much from those of patients in the late MDA 
group. If it were possible to predict achievement of MDA, patients at risk of not achieving MDA 
could be offered more intensive monitoring and earlier escalation of therapy.  
 Although analysis revealed a relation between time to MDA and HRQOL and 
productivity throughout the first year, a difference in radiological progression between the 3 
groups was not shown. We assume that this is the consequence of a lack of power resulting 
from the strong association with damage present at baseline and the low prevalence of 
progression of 14%. Several causes for this low prevalence can be proposed. First, the 1-year 
follow up was too short to demonstrate differences in this population. Second, radiological 
evaluation comprised assessment of hand and feet joints only, which are not necessarily the 
joints most often affected in for example oligoarthritis or monoarthritis patients. Third, disease 
activity in this usual care population at time of inclusion was lower than that in, for example, 
trial populations, for which higher progression rates have been reported.20, 21 
 In this observational cohort, all patients with a new diagnosis of PsA were eligible to 
participate. They all received usual clinical care and their outcomes are therefore reflective of 
current clinical care. Their treatment differed, however, as treatment was not protocolized. This 
heterogeneity of treatment could be a confounder of the relation between time to MDA and 
outcomes. However, as choice of treatment was associated with disease activity, correcting 
for baseline disease activity and use of DMARDs in the analyses reduced a substantial part of 
the confounding. Further, correcting for time to starting DMARD therapy and time on DMARD 
therapy did not alter the effects of MDA group on the outcomes. Unmeasured confounding 
by treatment could be present but likely has not affected our conclusion, given the small 
differences in treatment between the three groups.
 This study has several strengths and limitations. First, the population studied 
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reflects the population of PsA patients receiving usual care. Thus, our conclusions are better 
generalizable than those from trials or biological registries, where patient selection bias might 
have occurred. Second, reliability of the clinical data collection is ensured because data 
were collected by research nurses in a standardized manner during dedicated study visits. 
As a limitation, this could however introduce discrepancies between disease activity and 
treatment strategy, as the latter is determined by physicians based on their own assessment of 
disease activity, unaware of the nurse’s assessment. We, therefore, cannot exclude incomplete 
correction for confounding by disease activity, although we also corrected for DMARD therapy. 
Another limitation is the heterogeneity of treatment strategies, as discussed above. There is a 
possibility of selective drop-out of patients. It could well be that patients with early MDA are 
discharged from clinical care and are less likely to complete follow up and be included in our 
1-year analysis. As a consequence, the rates of MDA and productivity may be underestimated, 
in which case the true effect of MDA on productivity is even larger. Last, in our analysis of data 
after 1 year, we were not able to show a difference between groups in MDA within 1 year on 
outcomes at 1 year, but we might see a difference in future analyses of patients later in MDA 
and with longer follow up.  
CONCLUSION
In conclusion, gaining MDA in the first year after diagnosis was associated with considerable 
improvement in HRQOL and functioning, irrespective of time to first MDA. This improvement 
was not seen in a third of early PsA patients not in MDA in their first year after diagnosis, whose 
impact of disease remained as substantial as at the time of diagnosis. 
Chapter 5
8 4
1
2
3
4 
5 
6 
 
 
7 
8 
9 
10
11 
12 
13
14
15
16
17
18
19
Mease PJ. Psoriatic arthritis: update on 
pathophysiology, assessment and management. 
Ann Rheum Dis. 2011;70 Suppl 1:i77-84.
Husted JA, Gladman DD, Farewell VT, et al. 
Validating the SF-36 health survey questionnaire 
in patients with psoriatic arthritis. J Rheumatol. 
1997;24(3):511-7.
Gladman DD, Shuckett R, Russell ML, et al. 
Psoriatic arthritis (PSA)--an analysis of 220 
patients. Q J Med. 1987;62(238):127-41.
Wong K, Gladman DD, Husted J, et al. Mortality 
studies in psoriatic arthritis: results from a single 
outpatient clinic. I. Causes and risk of death. 
Arthritis Rheum. 1997;40(10):1868-72.
Gossec L, Smolen JS. European League Against 
Rheumatism (EULAR) recommendations for 
the management of psoriatic arthritis with 
pharmacological therapies: 2015 update. 
2016;75(3):499-510.
Coates LC, Kavanaugh A, Mease PJ, et al. 
Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis 2015 Treatment 
Recommendations for Psoriatic Arthritis. Arthritis 
Rheumatol. 2016;68(5):1060-71.
Stoffer MA, Schoels MM, Smolen JS, et al. Evidence 
for treating rheumatoid arthritis to target: results 
of a systematic literature search update. Ann 
Rheum Dis. 2016;75(1):16-22.
Smolen JS, Schols M, Braun J, et al. Treating 
axial spondyloarthritis and peripheral 
spondyloarthritis, especially psoriatic arthritis, 
to target: 2017 update of recommendations 
by an international task force. Ann Rheum Dis. 
2018;77(1):3-17.
Coates LC, Fransen J, Helliwell PS. Defining 
minimal disease activity in psoriatic arthritis: a 
proposed objective target for treatment. Ann 
Rheum Dis. 2010;69(1):48-53.
Queiro R, Canete JD, Montilla C, et al. Minimal 
disease activity and impact of disease in psoriatic 
arthritis: a Spanish cross-sectional multicenter 
study. Arthritis Res Ther. 2017;19(1):72.
Wervers K, Vis M, Tchetverikov I, et al. Burden of 
Psoriatic Arthritis in different definitions of disease 
activity: comparing Minimal Disease Activity 
and Disease Activity index for Psoriatic Arthritis. 
Arthritis Care Res (Hoboken). 2018; 70(12):1764-70
van Mens LJJ, Turina MC, van de Sande 
MGH, et al. Residual disease activity in 
psoriatic arthritis: discordance between the 
rheumatologist’s opinion and minimal disease 
activity measurement. Rheumatology (Oxford). 
2018;57(2):283-90.
Healy PJ, Helliwell PS. Measuring clinical 
enthesitis in psoriatic arthritis: assessment 
of existing measures and development of an 
instrument specific to psoriatic arthritis. Arthritis 
Rheum. 2008;59(5):686-91.
Fredriksson T, Pettersson U. Severe psoriasis--
oral therapy with a new retinoid. Dermatologica. 
1978;157(4):238-44.
Ware JE, Jr., Sherbourne CD. The MOS 36-item 
short-form health survey (SF-36). I. Conceptual 
framework and item selection. Med Care. 
1992;30(6):473-83.
Fries JF, Spitz P, Kraines RG, et al. Measurement 
of patient outcome in arthritis. Arthritis Rheum. 
1980;23(2):137-45.
Bouwmans C, Krol M, Severens H, et al. The iMTA 
Productivity Cost Questionnaire: A Standardized 
Instrument for Measuring and Valuing Health-
Related Productivity Losses. Value Health. 
2015;18(6):753-8.
van der Heijde D, Sharp J, Wassenberg S, et al. 
Psoriatic arthritis imaging: a review of scoring 
methods. Ann Rheum Dis. 2005;64 Suppl 2:ii61-4.
Kosinski M, Zhao SZ, Dedhiya S, et al. Determining 
minimally important changes in generic and 
REFERENCES
Time to MDA
8 5
5
20
21
disease-specific health-related quality of life 
questionnaires in clinical trials of rheumatoid 
arthritis. Arthritis Rheum. 2000;43(7):1478-87.
Kavanaugh A, Ritchlin C, Rahman P, et al. 
Ustekinumab, an anti-IL-12/23 p40 monoclonal 
antibody, inhibits radiographic progression in 
patients with active psoriatic arthritis: results of an 
integrated analysis of radiographic data from the 
phase 3, multicentre, randomised, double-blind, 
placebo-controlled PSUMMIT-1 and PSUMMIT-2 
trials. Ann Rheum Dis. 2014;73(6):1000-6.
Mease P, van der Heijde D, Landewe R, et al. 
Secukinumab improves active psoriatic arthritis 
symptoms and inhibits radiographic progression: 
primary results from the randomised, double-
blind, phase III FUTURE 5 study. Ann Rheum Dis. 
2018;77(6):890-7.

C H A P T E R  6
Burden of Psoriatic Arthritis according to 
different definitions of disease activity: 
comparing Minimal Disease Activity  and the 
Disease Activity index for Psoriatic Arthritis
Kim Wervers
Marijn Vis
Ilja Tchetverikov
Andreas H. Gerards
Marc R. Kok
Cathelijne W.Y. Appels
Wiebo L. van der Graaff
Johannes H.L.M. van Groenendael
Lindy-Anne Korswagen
Josien J Veris-Van Dieren
Johanna M. W. Hazes
Jolanda J. Luime 
 
Arthritis Care Res. 2018 Dec;70(12):1764-1770
Chapter 6
8 8
ABSTRACT
Objective: Treat-to-target strategies have improved outcomes in rheumatic diseases. In 
psoriatic arthritis (PsA), the proposed targets are the multidimensional target Minimal Disease 
Activity (MDA) and the articular target Disease Activity index for PsA (DAPSA). The aim of this 
study was to compare the disease burden of PsA in patients with low disease activity according 
to the two definitions, MDA and DAPSA-low disease activity (DAPSA-LDA), 1 year after diagnosis. 
Methods: We obtained data on MDA, DAPSA-LDA and disease burden 1 year after diagnosis for 
patients included in the Dutch southwest early PsA cohort. Disease burden was assessed in 2 
domains: “Body functions”, including the Short Form 36 Bodily Pain (SF36-BP) measure, and 
“Activity”, including the Health Assessment Questionnaire (HAQ). 
Results: Among the 292 patients included, 48% achieved MDA and 74% achieved DAPSA-LDA. 
Average scores for Body functions and Activity were better in patients who achieved MDA and 
those who achieved DAPSA-LDA. The scores were significantly better in the 46% of patients 
who achieved both MDA and DAPSA-LDA than in the 29% of patients who achieved only 
DAPSA-LDA. The average SF-36 BP score was higher in patients achieving both targets (73.8, 
95% confidence interval [95% CI] 71.1-76.5) than in patients achieving only DAPSA-LDA (57.6, 
95% CI 54.5-60.8). Similarly, mean HAQ scores measuring Activity were 0.21 (95% CI 0.15-0.26) 
and 0.63 (95% CI 0.53-0.72), respectively. 
Conclusion: Among patients with newly diagnosed PsA, 48% achieved MDA and 74% 
achieved DAPSA-LDA after 1 year of receiving usual care. The average disease burden was 
better in patients who achieved MDA than those who achieved DAPSA-LDA. Also, patients who 
achieved only DAPSA-LDA reported worse outcomes than those who also achieved MDA. 
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INTRODUCTION
Psoriatic arthritis (PsA) belongs to the group of spondyloarthritides and is a heterogenic disease 
that involves both the skin (skin and nail psoriasis) and musculoskeletal features (arthritis, 
enthesitis spondylitis and dactylitis).1, 2 Without treatment, most patients with PsA experience 
progressive joint damage and increasing disability and have a reduced life expectancy.3-5 
 Outcomes in rheumatic diseases have improved substantially over the last decades, 
largely due to the introduction of new therapies6 and their use in treat-to-target strategies.7 
The objective of treat-to-target strategies is to achieve remission or a low or minimal disease 
activity state. Such a state of disease signifies that the disease burden at that time is low and 
long term worsening of functioning, quality of life and joint erosion are prevented. The TICOPA 
study has shown that a treat-to-target strategy is also effective in PsA cases.8 In clinical practice 
however, treat-to-target has not been implemented in PsA as successfully as in rheumatoid 
arthritis. One of the main reasons is the lack of consensus on what the target should be in PsA. 
This is among other things related to the heterogenic nature of PsA. In the first trials in PsA, 
treatment effect was measured with targets used in rheumatoid arthritis and consequently 
mainly effects on arthritis were measured.9 However, other disease manifestations, such as 
psoriasis, enthesitis and dactylitis, are considered important as well.10 It is unknown whether 
inclusion of manifestations other than arthritis in a treatment target is associated with better 
patient outcomes. 
 Different disease activity measures have been proposed as treatment targets, such as 
the Psoriatic Arthritis Disease Activity Score, the Composite Psoriatic arthritis Disease Activity 
Index, the Disease activity index for Psoriatic Arthritis (DAPSA) and Minimal Disease Activity 
(MDA).11-14 Of these measures, MDA and the DAPSA have recently both been recommended by 
international experts as the main targets.15 A patient is considered to be in MDA if at least 5 out 
of 7 remission criteria are met. Remission is assessed by tender joint count in 68 joints (TJC68) 
and the swollen joint count in 66 joints (SJC66), psoriasis, enthesitis, patient’s global and 
pain assessment as measured on a Visual Analogue Scale (VAS), and the Health Assessment 
Questionnaire (HAQ).16 The DAPSA score is calculated using scores in TJC68 and SJC66 scores, 
patient’s global and pain scores on a VAS, and the C-reactive protein (CRP) level.11 DAPSA ≤ 14 
represents a state of low disease activity (DAPSA-LDA), and a score of ≤ 4 represents remission 
(DAPSA-REM).17 In contrast with MDA, DAPSA is a unidimensional target that mainly measures 
articular involvement.15 Before choosing either one of the targets, more information is needed 
regarding how they relate to outcomes relevant to patients. Therefore, the aim of our study was 
to compare the PsA disease burden in patients with LDA according to the 2 different definitions, 
MDA and DAPSA-LDA, 1 year after diagnosis. In addition, we sought to determine which aspect 
of disease activity prevented patients from achieving MDA or DAPSA-LDA. Disease burden 
was assessed using the International Classification of Functioning, Disability and Health (ICF) 
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domains ‘Body functions’ and ‘Activity’.18 
PATIENTS AND METHODS
Patients and Setting
We used data collected from the Dutch southwest Early Psoriatic Arthritis cohoRt (DEPAR). 
Patients with newly diagnosed PsA were invited to participate in DEPAR. The diagnosis of PsA 
was made according to the expert opinion of the participating rheumatologists. All eligible 
patients with newly diagnosed PsA (ages ≥ 18 years and with no current treatment with disease-
modifying antirheumatic drugs [DMARDs] for joint symptoms) were asked to participate. Use of 
DMARDs for psoriasis and use of nonsteroidal anti-inflammatory drugs (NSAIDs) were allowed. 
Patients were recruited in centers in the south-west region of the Netherlands (1 academic 
hospital, 10 general hospitals and 1 treatment center specializing in rheumatic disease care). 
Written informed consent was obtained from all participants according to the Declaration of 
Helsinki. The study was approved by the local medical research ethics committee at Erasmus 
Medical Center Rotterdam, the Netherlands (approval no. MEC-2012-549). Data from patients 
who were included between August 2013 and June 2017 were used. For this analysis, we used 
data 1 year after diagnosis and inclusion in DEPAR. 
Patient and disease characteristics
Trained research nurses collected clinical data, including the SJC66 and TJC68, enthesitis 
at time of clinical examination (Leeds Enthesitis Index [LEI]19), dactylitis (Leeds Dactylitis 
Index [LDI]20) and psoriasis (Psoriasis Area and Severity Index [PASI]21). Patients filled out 
questionnaires shortly before or after their visit to the research nurse. Multiple questionnaires 
are used to measure patient-reported disease activity and different outcomes, such as 
health-related quality of life. For this analysis we used the Short Form-36 (SF-3622), the HAQ23, 
patient’s global and pain scores on a VAS and the Bristol Rheumatoid Arthritis Fatigue (BRAF24) 
questionnaire. 
Primary outcome 
The impact of disease activity status as measured by MDA and DAPSA on the burden of 
disease was assessed in 2 domains of the World Health Organization (WHO) ICF.18 The primary 
outcomes in the ‘Body functions’ domain were Bodily Pain (BP) as measured with the SF-36 
and fatigue measured by the BRAF. In the ‘Activity’ domain the primary outcomes were Physical 
Functioning (PF) as measured by the SF-36 and HAQ scores. The range of scores for both SF-36 
BP and SF-36 PF is 0-100, with a higher score representing better health status. For BRAF scores 
(range 0-70) and HAQ scores (range 0-3), a lower score represents better health status. 
PsA burden in MDA and DAPSA
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Disease activity status
Disease activity status was assessed using MDA and DAPSA. MDA is defined as having met at 
least 5 out of 7 remission criteria (SJC66 ≤ 1, TJC68 ≤ 1, LEI ≤ 1, PASI ≤ 1, patient’s global score ≤ 
2.0 cm [VAS], patient’s pain score ≤ 1.5 cm [VAS], HAQ score ≤ 0.5). In addition, we determined 
which patients had achieved Very Low Disease Activity (VLDA), which is a stricter form of MDA 
in which all remission criteria for the MDA must be met.25 The DAPSA was calculated as TJC68 + 
SJC66 + patient’s global assessment score (VAS, cm) + pain’s pain assessment score (VAS, cm) 
+ CRP. Categories of DAPSA were DAPSA-LDA (DAPSA score ≤ 14) and DAPSA-REM (DAPSA score 
≤ 4).11, 17  Residual disease activity in the SJC66, TJC68, LEI, PASI, patient’s global assessment 
score, patient’s pain score, HAQ, dactylitis and CRP level was determined. 
Statistics
Patient characteristics and fulfillment of targets were described using simple descriptive 
analysis techniques. First, the average disease burden in patients who had achieved MDA, 
DAPSA-LDA, VLDA or DAPSA-MDA was compared. Second, we tested whether patients with 
MDA had also achieved DAPSA-LDA and vice versa, or whether patients had a different disease 
status according to the 2 definitions. We compared disease burden in these categories as well, 
using ANOVA and t-tests. STATA 14.0 was used. 
RESULTS
Achieving low disease activity
292 (58%) of 504 patients had attended their 12-months follow-up visit at time of the analysis. 
Their mean ± SD age was 51 ± 14 years, 150 were male (51%) and median symptom duration 
before diagnosis was 12 months (interquartile range 4-32) (Table 1). At the 12-month follow-up 
visit, 48% of patients had achieved in MDA and 74% had achieved DAPSA-LDA. According to 
stricter criteria, 13% of patients had achieved VLDA, and 32% had achieved DAPSA-REM (Figure 
1). In 234 of the 292 patients, both DAPSA and MDA status were known. Reasons for missing 
data included incomplete questionnaires (40 patients) and missing CRP values (18 patients). 
Of these 234 patients, 58 (25%) had achieved neither DAPSA nor MDA, 67 (29%) had achieved 
DAPSA-LDA but not MDA, 2 (1%) had achieved MDA but not DAPSA-LDA, and 107 (46%) had 
achieved both MDA and DAPSA-LDA. 
Disease burden according to different definitions of low disease activity
Disease burden was assessed using the WHO ICF domains ‘Body functions’ and ‘Activity’ and 
the average scores of patients with a low disease status according to different definitions were 
compared. Body functions were better in patients with MDA than in patients with DAPSA-
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Table 1. Characteristics of the 292 patients at time of diagnosis
Age, mean ± SD years 51 (14)
Male sex, n (%) 150 (51)
Duration of symptoms, median (IQR) months 12 (4 - 32)
TJC68, median (IQR) 3 (1 - 8)
SJC66, median (IQR) 2 (1 - 5)
HAQ score, median (IQR)* 0.63 (0.25 - 1.00)
Elevated CRP level, n (%)# 71 (29)
*41 missing questionnaires
#103 missing values. 
SD: standard deviation; IQR: interquartile range; TJC68: tender joint count in 68 joints; SJC66: swollen joint count in 66 
joints; HAQ: Health Assessment Questionnairre; CRP: C-reactive Protein.
LDA as measured with SF-36 BP and BRAF. These scores were again slightly better in patients 
fulfilling the stricter VLDA and DAPSA-REM criteria. The mean SF-36 BP score was 73.6 (95% 
CI 70.9-76.3) in patients who achieved MDA, 67.6 (95% CI 65.2-69.9) in those with DAPSA-LDA, 
83.0 (95% CI 78.5-87.4) in those with VLDA, and 77.3 (95% CI 74.1-80.6) in those who achieved 
DAPSA-REM (Figure 2). Similarly, impact on the domain Activity was significantly better in 
patients in MDA than those who achieved DAPSA-LDA, and was even better in those with VLDA 
Figure 1. Percentages of patients fulfilling definitions of low disease activity
MDA: Minimal Disease Activity; DAPSA-LDA: Disease Activity index for Psoriatic Arthritis – Low Disease Activity (DAPSA ≤ 
14); VLDA: Very Low Disease Activity; DAPSA-REM: DAPSA Remission (DAPSA ≤ 4).
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Figure 2. ‘Body functions’ within different definitions of low disease activity
Data shown as mean with 95% confidence intervals. 
SF-36: Short Form-36; BP: Bodily Pain; BRAF: Bristol Rheumatoid Arthritis Fatigue; MDA: Minimal Disease Activity; 
DAPSA-LDA: Disease Activity index for Psoriatic Arthritis – Low Disease Activity (DAPSA ≤ 14); VLDA: Very Low Disease 
Activity; DAPSA-REM: DAPSA Remission (DAPSA ≤ 4). 
and those with DAPSA-REM (Figure 3). The mean SF-36 PF scores were 85.8 (95% CI 83.1-88.4) 
in patients who achieved MDA, 79.7 (95% CI 77.1-82.3) in those with DAPSA-LDA, 92.8 (95% CI 
89.6-96.0) in those with VLDA, and 88.5 (95% CI 85.3-91.8) in those who achieved DAPSA-REM. 
The mean HAQ score were 0.22 (95% CI 0.17-0.27) in the MDA group, 0.37 (95% CI 0.31-0.43) in 
the DAPSA-LDA group, 0.06 (95% CI 0.02-0.10) in the VLDA group, and 0.16 (95% CI 0.10-0.22) in 
the DAPSA-REM group. 
 Measures of Body functions were significantly better in patients with both MDA and 
DAPSA-LDA than in patients with only DAPSA-LDA; mean SF-36 BP scores 73.8 (95% CI 71.1-
76.5) and 57.6 (95% CI 54.5-60.8), respectively, and mean BRAF scores 11.8 (95% CI 9.8-13.9) 
and 20.8 (95% CI 17.7-23.9), respectively. A similar outcome was observed for measures of 
Activity; mean SF-36 PF scores 86.0 (95% CI 83.2-88.9) and 69.6 (95% CI 65.6-73.7), respectively, 
and mean HAQ scores 0.21 (95% CI 0.15-0.26) and 0.63 (95% CI 0.53-0.72), respectively. There 
was no statistically significant difference in Body functions and Activity between patients who 
achieved both MDA and DAPSA and those who achieved only MDA  (Supplemental Figure 1 and 
Supplemental Figure 2, patients who achieved MDA but not DAPSA-LDA not shown because of 
small sample size). 
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Residual disease activity
In patients with low disease activity according to criteria for MDA or DAPSA, main areas of 
residual disease activity were the tender joints, psoriasis, patient’s global assessment and pain 
assessment scores, and HAQ scores.  These percentages were slightly higher in patients who 
achieved DAPSA-LDA than in those who achieved only MDA. None of the patients in VLDA had 
any residual disease activity. Clinical enthesitis, dactylitis and an elevated CRP level were rarely 
observed in all definitions of low disease activity (Table 2).  In patients who had not achieved 
MDA, the domains with the highest residual activity were patient’s pain score (91%), patient’s 
global score (86%), HAQ score (67%), TJC68 (61%), and psoriasis (59%) (Table 3). More than 
1 joint was swollen in 27%, and more than 1 clinical manifestation of enthesitis was present 
in 24% (LEI score > 1). Residual activity in patients who did not fulfill DAPSA-LDA criteria was 
similar to that in patients who did not fulfill the MDA criteria, except more patients in the former 
group had more than one tender joint (85%). Dactylitis in more than one digit was rarely 
observed. The patients who achieved only DAPSA-LDA most often had residual disease activity 
in patient’s pain score (88%) and patient’s global assessment score (78%), which prevented 
them from achieving MDA (Supplemental table 1). 
Figure 3. ‘Activity’ within different definitions of low disease activity 
Data shown as mean with 95% confidence intervals. 
SF-36: Short Form-36; PF: Physical Functioning; HAQ: Health Assessment Questionnaire; MDA: Minimal Disease 
Activity; DAPSA-LDA: Disease Activity index for Psoriatic Arthritis – Low Disease Activity (DAPSA ≤ 14); VLDA: Very Low 
Disease Activity; DAPSA-REM: DAPSA Remission (DAPSA ≤ 4). 
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DISCUSSION
In patients receiving usual care, in which treatment is not directed at achieving a specific PsA 
target, we did not observe large differences in average disease burden between PsA patients 
who achieved either MDA or DAPSA-LDA. In addition, we showed that patients with MDA 
usually also were had DAPSA-LDA. In contrast, not all patients with DAPSA-LDA had achieved 
Table 2. Residual disease activity in patients with low disease activity
MDA 
(n=127)
DAPSA ≤ 14 
(n=174)
VLDA 
(n=34)
DAPSA ≤ 4 
(n=75)
TJC68 > 1 9 21 0 3
SJC66 > 1 6 13 0 3
PASI score > 1 34 45 0 41
Pain score  > 1.5 (0-10 cm VAS) 26 48 0 17
Global score >2.0 (0-10 cm VAS) 18 41 0 4
HAQ score > 0.5 7 25 0 9
LEI score >1 1 6 0 3
Dactylitis  2 2 0 1
Elevated CRP level 6 10 0 3
Data shown as percentage of patients with residual disease activity. 
TJC68: tender joint count in 68 joints; SJC66: swollen joint count in 66 joints; PASI: Psoriasis Area and Severity Index; 
VAS: Visual Analogue Scale; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; CRP: C-reactive 
protein; MDA: Minimal Disease Activity; DAPSA: Disease Activity index for Psoriatic Arthritis; VDLA: Very Low Disease 
Activity. 
Table 3. Residual Disease Activity in patients with high disease activity
 No MDA 
(n=137)
DAPSA > 14 
(n=60)
no VLDA 
(n=218)
DAPSA > 4 
(n=159)
TJC68 > 1 61 85 42 54
SJC66 > 1 27 33 20 25
PASI score > 1 59 53 54 50
Pain score  > 1.5 (0-10 cm VAS) 91 98 70 82
Global score >2.0 (0-10 cm VAS) 86 95 63 79
HAQ score > 0.5 67 82 45 54
LEI score >1 24 32 31 17
Dactylitis  3 3 3 3
Elevated CRP level 16 17 14 16
Data shown as percentage of patients with residual disease activity. 
TJC68: tender joint count in 68 joints; SJC66: swollen joint count in 66 joints; PASI: Psoriasis Area and Severity Index; 
VAS: Visual Analogue Scale; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; CRP: C-reactive 
protein; MDA: Minimal Disease Activity; DAPSA: Disease Activity index for Psoriatic Arthritis; VDLA: Very Low Disease 
Activity. 
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MDA. In a subsequent analysis of the  burden of disease in these patients, we showed that 
patients achieving both targets reported better Body functions and Activity compared with 
those achieving only DAPSA-LDA. It seems that this subgroup of patients warranted more 
attention but were regarded as having low disease activity as determined using the DAPSA 
score. No or very little residual disease activity was measured in patients achieving VLDA or 
DAPSA-REM. However, only 13% of patient receiving usual care reached that target.
 Our study is unique in the sense that we compared different targets and their 
relationship to the disease burden in patients with early PsA. Previous studies have shown 
high agreement between MDA and DAPSA; however the investigators in those studies were not 
able to determine whether these groups differed in terms of disease burden.26, 27 Investigators 
in other studies did assess the burden of disease in patients fulfilling only 1 of the targets 
compared with those not fulfilling that target. It was shown in those studies that patients 
achieving the target had better scores for patient-reported outcomes compared with patients 
in whom the target as not achieved.28-31 
 Besides the target being related to better outcomes, it should also be feasible to use in 
clinical practice. In patients with MDA, the presence of enthesitis, dactylitis, and psoriasis must 
be assessed additionally, although such an assessment probably was done during routine 
care, because the recommended treatment depends on the domain involved.32, 33 In contrast, 
a high DAPSA score indicates that treatment should be intensified, but it is less informative 
for determining how it should  be intensified, because the choice of treatment depends on 
the domains involved. One of the reasons why patients who achieve both MDA and DAPSA 
report better outcomes than patients who achieve only DAPSA-LDA, is that the HAQ is also 
included in the criteria for MDA. A higher HAQ score in the patients who achieved DAPSA only 
could be the result of these patients not achieving MDA because of a high HAQ score. However, 
patients with only DAPSA-LDA also had higher PASI scores, global and pain scores, and higher 
SJC66 and TJC68 scores. The impact of psoriasis was recently demonstrated by Mease et al.,29 
in which patients enrolled in the Consortium of Rheumatology Researchers of North America 
Registry who had greater skin involvement more often had not achieved MDA and also had 
poorer functional status. Furthermore, the overall burden of disease in patients with MDA did 
not change when we excluded the HAQ score as a remission criterion for MDA. 
 Studying the true value of different targets in the treatment of PsA ideally would 
be investigated in a large randomized clinical trial, studying treat-to-target strategies, and 
randomizing patients to treat-to-target care with different targets. Such data are currently 
not available. Therefore, we used the second-best alternative, a large observational cohort 
of patients with early PsA. Use of this approach causes some challenges in interpreting the 
results. Rheumatologists were not instructed to treat patients according to a certain target. 
We do not know whether treatment would have differed between patients treated to target 
with either MDA or DAPSA, if they would have been randomized. In the current study, after 
PsA burden in MDA and DAPSA
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12 months of treatment, patients achieving only DAPSA-LDA had a higher burden of disease 
compared with patients who achieved both targets. Whether this gap would have been 
resolved with treatment remains to be determined. For example, comorbidities could influence 
the subjective elements of disease activity.34, 35 Irrespective of the disease activity measure that 
is used, in daily clinical care disease activity always needs to be interpreted by the treating 
physician. A second challenge in the interpretation of our results is that in this real life cohort 
study, selection bias may have occurred. Some patients were lost to follow up and did not 
have a 12-month assessment. This occurrence could be related to disease activity as well, 
because some patients were discharged from care by the rheumatologist and subsequently 
did not visit the research nurse when invited. The data we present are representative of the 
population visiting the rheumatologist 1 year after diagnosis, instead of all patients 1 year after 
diagnosis.  
 In conclusion, in our study of early PsA, no large differences were observed in the 
disease burden between patients achieving MDA or DAPSA-LDA while receiving current usual 
care, because most patients who achieved MDA also achieved DAPSA-LDA. However, patients 
who reached both targets reported better Body functions and Activity compared with those 
who achieved only DAPSA-LDA. It appears that MDA is more difficult to achieve, but aiming for 
MDA even after DAPSA-LDA is achieved potentially results in better outcomes for patients.
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SUPPLEMENTAL DATA
Supplemental Figure 1. Body Functions in categories of MDA and DAPSA
Data shown as mean with 95% confidence intervals. 
SF-36: Short Form-36; BP: Bodily Pain; BRAF: Bristol Rheumatoid Arthritis Fatigue; MDA-: not in Minimal Disease Activity 
(MDA); MDA+: in MDA; DAPSA-: not in  Disease Activity index for Psoriatic Arthritis – Low Disease Activity (DAPSA > 14); 
DAPSA+: in DAPSA-LDA (DAPSA ≤ 14).
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Supplemental Figure 2. Activity in categories of MDA and DAPSA
Data shown as mean with 95% confidence intervals. 
SF-36: Short Form-36, PF: Physical Functioning: HAQ: Health Assessment Questionnaire, MDA-: not in Minimal Disease 
Activity (MDA); MDA+: in MDA; DAPSA-: not in  Disease Activity index for Psoriatic Arthritis – Low Disease Activity (DAPSA 
> 14); DAPSA+: in DAPSA-LDA (DAPSA ≤ 14). 
Supplemental Table 1. Residual Disease Activity in MDA and DAPSA categories
MDA - MDA +
 DAPSA -
(n=58)
DAPSA +
(n=67)
DAPSA - 
(n=2)
DAPSA + 
(n=107)
TJC68 > 1 86 40 50 9
SJC66 > 1 33 22 50 7
PASI score > 1 55 58 0 36
Pain score  > 1.5 (0-10 cm VAS) 100 88 50 23
Global score >2.0 (0-10 cm VAS) 97 78 50 18
HAQ score > 0.5 84 54 0 7
LEI score >1 33 13 0 1
Dactylitis  3 3 0 2
Elevated CRP level 16 18 50 6
Percentage of patients with residual disease activity. 
TJC68: tender joint count in 68 joints; SJC66: swollen joint count in 66 joints; PASI: Psoriasis Area and Severity Index, 
VAS: Visual Analogue Scale, HAQ: Health Assessment Questionnaire, LEI: Leeds Enthesitis Index, CRP: C-reactive 
protein, MDA: Minimal Disease Activity, DAPSA: Disease Activity index for Psoriatic Arthritis.
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Psoriatic arthritis (PsA) is a heterogeneous disease, in which patients can suffer from 
different musculoskeletal and dermatological manifestations. With treatment, the disabling 
consequences of the disease can be altered, and the chances of doing so are probably highest 
at an early stage of the disease.1-4 We do however need more knowledge on disease activity 
and outcomes at time of diagnosis and in the early course of disease. The aims of this thesis 
therefore were to investigate in early PsA: 
• ultrasound abnormalities of the entheses
• burden of disease at time of diagnosis and its relation with disease manifestations
• the relation between time to minimal disease activity and outcomes
• performance of disease activity measures
These questions were addressed in the DEPAR study (Dutch southwest Early Psoriatic Arthritis 
cohoRt) and its sub-studies. Patients with a new diagnosis of PsA were eligible to participate 
in DEPAR. They were seen for a baseline assessment before starting treatment with disease-
modifying antirheumatic drug (DMARD) therapy for PsA. DMARD use with indication of psoriasis 
and use of non-steroidal anti-inflammatory drugs were allowed. Patients visited research 
nurses for clinical assessment and completed questionnaires every 3 months in their first 
year after inclusion. A subset of patients underwent sonographic evaluation of the entheses 
at baseline, and these data were compared with those of patients with established disease 
and with those young, healthy volunteers. In a second sub-study, a larger group of established 
PsA patients were assessed, together with an older control group of healthy volunteers, to 
determine which clinical factors in PsA patients were associated with having ultrasound 
abnormalities. 
ULTRASOUND ABNORMALITIES OF THE ENTHESES
Though it is well known that enthesitis is a manifestation of PsA, no gold standard or a definition 
of the diagnosis is available. There is an abundance of evidence showing enthesitis is related to 
PsA: patients report complaints and tenderness of entheses at clinical examination; in imaging 
abnormalities we recognize signs of inflammation and signs of structural consequences 
of chronic inflammation;5, 6 and in clinical trials in which medication aimed at reducing 
inflammation is tested, patients report improvement of their pain in the entheses.7 Several 
researchers even propose that enthesitis could be the primary source of inflammation and 
synovitis is a result of extension of inflammation at the enthesis.8 Our clinical interest however 
is the individual patient, for whom it needs to be decided whether or not treatment is indicated 
because of PsA-related enthesitis. 
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 In an individual patient, it is often difficult to determine presence of enthesitis with 
clinical examination alone. Tendon complaints occur frequently in the healthy population,9, 
10 and are related to several other causes, such as metabolic, degenerative or mechanical 
pathologies.11 The presence of inflammatory enthesitis might be distinguished from other 
pathologies with imaging, as is done with ultrasound in patients suspected of arthritis. In 
these patients, grey-scale signs of synovitis and presence of power Doppler (PD) as a measure 
of increased vascularisation are interpreted as indicators of inflammation.12 The same 
interpretation has been applied to the enthesis, but entheseal tissue differs substantially from 
synovial tissue. The enthesis has a more tight, fibrillary organisation, is barely vascularized or 
innervated, and is known to regenerate at a slow rate.8 Inflammation of the enthesis might 
give a different aspect on ultrasound than arthritis or might be less visible, so we need more 
knowledge on the difference in aspect of entheses of PsA patients and healthy volunteers. 
 In the first ultrasound study, we performed a comparison of extreme cases. For 
the study of ‘normal’ enthesis, we chose to investigate the entheses of young, healthy 
volunteers as we expected their entheses to be fully matured, but having suffered the least 
possible degenerative, mechanical or metabolic stress. Interestingly, many signs we would 
have interpreted as active inflammation on ultrasound were present in these young, healthy 
volunteers, as well as in the older healthy control we investigated in the second ultrasound 
study. This left us questioning whether these sonographic signs were truly related to 
inflammation or rather reflected normal physiology.
 The signs suggestive of enthesitis that were frequently present in healthy volunteers 
were increased thickness and PD signal. With respect to increased thickness, we strongly 
suspect that the reference values used in the MAdrid Sonographic Enthesitis Index (MASEI) 
are not suitable for all entheses. This could be caused by the way these references values were 
determined. For example, for the cut-off for the proximal and distal patellar tendon entheses, 
data from cadaveric limbs of humans aged 67 to 87 were used.13 We chose to exclude the 
assessment of increased thickness of all knee entheses as it did not seem that specific to 
entheses of PsA patients. Alternatively, age and gender specific reference values or the aspect 
of the entheses (e.g. a bulging aspect) could be used in the assessment of increased thickness. 
Also, considering that the young, healthy volunteers had a more physically active life style and 
suffered less from obesity than patients, we suspected increased thickness and PD signals 
were part of the physiological reaction of entheses to physical activity. These signs were also 
found more often in patients that reported not to avoid physical activity.  
 Not all that glittered was enthesitis related to PsA, but we certainly did observe 
differences between entheses of patients and those of healthy volunteers. Patients with PsA 
had in fact more structural damage of the entheses, both compared with young volunteers 
and with an older control group of healthy volunteers. This is seen in other studies comparing 
PsA and healthy volunteers as well.14, 15 These signs of structural damage of the entheses could 
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be interpreted as cumulative exposure of the entheses to inflammation and as a sign of PsA. 
In our multivariable analysis of factors associated with structural damage within PsA patients, 
only age was associated with structural damage. It is suggestive for an effect of time. Corrected 
for age, disease duration had no additional association with structural damage, but both 
are strongly correlated. To test the prognostic value of structural changes of the entheses on 
ultrasound, prospective observational studies are needed. 
 Our studies of ultrasound in enthesitis had an exploratory nature. We did not have 
the power to assess less strong effects or effects with a low prevalence. Also, both studies 
have a cross-sectional design, which means that we could not assess the direction of the 
relationship. We realize that the relations between physical activity, avoiding of physical 
activity, obesity, disease activity, and medication use are not captured in a single model, even 
without considering their impact on ultrasound of the entheses. These need to be studied in 
observational studies, preferably one investigating the efficacy of physical activity or medical 
therapy on enthesitis. Instead of trying to diagnose enthesitis, we could test whether imaging 
is able to diagnose therapy-responsive enthesitis. 
BURDEN OF DISEASE AT TIME OF DIAGNOSIS
At time of diagnosis and before starting treatment for PsA, patients had a significantly reduced 
health-related quality of life (HRQOL). The disease had a clinically relevant impact on mental 
aspects of HRQOL, and an even bigger impact on the physical aspects of HRQOL. Reduction 
of HRQOL was highest in those patients reporting more tender joints, enthesitis at clinical 
examination, chronic back pain, or a combination of those. The number of swollen joints, 
presence of dactylitis and severity of psoriasis had no additional impact on HRQOL at the time 
of diagnosis. Our data affirm the importance of taking all manifestations into account when 
choosing treatment, because manifestations other than arthritis also add to the burden of 
disease.
 The vast majority of patients in DEPAR received methotrexate as first treatment, 
indicating that arthritis is initially the main focus of therapy, despite presence of other 
manifestations. The European League Against Rheumatism (EULAR) and the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines for treatment 
of PsA, however, recommend not to use methotrexate if manifestations of enthesitis or axial 
involvement are also present. Reluctance to adhere to these guidelines could be explained 
by the level of evidence for each of the recommendations, which is higher for treatment of 
arthritis and psoriasis than it is for that of other manifestations. Enthesitis is only a secondary 
outcome in trials including patients with severe arthritis and/or severe psoriasis.7 Also, 
absence of evidence might be interpreted as evidence of absence: many DMARDs and other 
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therapies such as physical therapy have not been studied in randomized controlled trials. 
Similarly, methotrexate is used extensively because of clinical experience rather than because 
of evidence from randomized trials. We have shown that these other manifestations are very 
relevant to patients, so more evidence of treatment effects of these other manifestations is 
needed. 
 A second explanation for the reluctance to choose other treatment than methotrexate, 
is the uncertainty of these other manifestations being related to PsA, as we have described 
above for enthesitis. With respect to disease activity, pain and HRQOL, physicians are 
exceptionally often concerned with the phenomenon of fibromyalgia. We indeed believe that 
comorbidities, fibromyalgia being one of them, modify the relation between disease activity 
and HRQOL and that in some patients, PsA treatment will not improve HRQOL. Fibromyalgia is 
characterized by widespread pain, while many patients in our cohort reported having only one 
or a few tender entheses. Also, trials have shown that enthesitis indeed can be improved with 
biological DMARDs, confirming an inflammatory origin.7 Further, fibromyalgia is a diagnosis per 
exclusionem: it can only be diagnosed if  the pain cannot be explained by another disorder.16 
At time of PsA  diagnosis, pain is more likely to be related to inflammation than to structural 
damage or central sensitization. PsA-related enthesitis should not be miscalled fibromyalgia, 
as it might lead to underestimation of disease burden and possibly deprivation of effective 
therapy. 
 Similar to the problem of relating enthesitis to PsA, diagnosing axial involvement 
cannot be done with clinical evaluation alone. Many believe the pattern of back involvement 
in patients with PsA differs from the pattern in patients with axial SpA.17, 18 Aydin et al. reported 
that the Assessment of Spondyloarthritis international Society criteria for inflammatory back 
pain have a lower sensitivity in PsA than in axial SpA, which could lead to underdiagnosis of 
axial involvement in PsA.19 In our study, a few patients were diagnosed with a predominantly 
axial phenotype, but axial involvement could be present in other patients as well. We showed 
that chronic back pain is an important determinant of HRQOL in patients, suggesting that 
more attention to axial involvement in PsA is justified. 
 Our findings of disease burden and its relation with manifestations can be translated 
to patients with a new diagnosis, but this relation might change with progression of the 
disease. The pattern of manifestations is known to change over time within patients,20 and use 
of coping mechanisms might change impact of disease manifestations by means of response 
shift. The relation should be studied longitudinally, to assess whether burden of disease is 
relieved if the manifestations are treated successfully.  
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TIME TO MINIMAL DISEASE ACTIVITY
We hypothesized that patients who were treated successfully earlier in the disease had better 
outcomes 1 year after diagnosis than patients in whom treatment was successful later. We 
defined successful treatment as achieving Minimal Disease Activity (MDA), and related this 
to outcomes at 1 year after diagnosis. We found a third of patients was in MDA early and a 
third late, and a third was not in MDA in the first year after diagnosis of PsA. In patients who 
achieved MDA, disability and burden of disease improved once MDA was achieved. Patients 
in the early group were significantly longer in MDA in the first year, and consequently, they 
had lower burden and better physical functioning throughout the first year. The late group 
benefitted less from achieving MDA throughout the first year, but were still able to achieve the 
same level of physical functioning and disease burden as patients who achieved MDA early. 
From the perspective of outcomes after 1 year, the therapeutic window of opportunity has 
not closed after the first 3 months after diagnosis of PsA.  Future studies of longer follow up of 
these patients are needed, to assess whether disease activity and outcomes remain similar for 
patients who have achieved MDA in their first year after diagnosis. 
 Patients who achieved MDA early had lower disease activity and lower disease burden 
at baseline, and had sooner reached a stable level of functioning than patients achieving MDA 
late. Those patients reached a similar level, despite higher disease activity and higher disease 
burden at baseline. The optimistic interpretation is that no damage has been done and all is 
reversible in the first year. We do however not know what the maximum achievable physical 
functioning is, would they have been achieved MDA earlier. A pessimistic interpretation is  that 
patients who achieved MDA early should have had a higher potential than those who achieved 
MDA late, and underestimation of severity at the start has led to under treatment. This might 
also be related to the manifestations and the predominant phenotype at time of diagnosis.
 Patients that achieved MDA late or not at all within the first year seemed comparable 
at time of diagnosis, with similar disease activity and disease burden. If we were able to predict, 
at time of diagnosis, whether the time to achieving MDA will be longer, we may be able to 
intervene earlier. These patients may benefit from being monitored more closely or having 
treatment escalated more quickly. A subject of future research is longer follow up of these 
patients that did not achieve MDA within a year. That will show whether these patients will be 
able to achieve MDA after 1 year, and if so, whether they are able to reach similar improvement 
of burden of disease and functioning.  
 One of the goals of treatment is preventing structural damage. We hypothesized 
that radiological progression would be lower if the target of MDA had been achieved early. 
This hypothesis was not confirmed by the data. In total, 14% of patients had radiological 
progression, and this was seen in all MDA groups. There are several explanations for the 
low progression rates. First, we assessed a usual care population with follow-up 1 year after 
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diagnosis of PsA. The effects of slightly longer high disease activity within the first year might 
become apparent later in the disease, or the effects might not be destructive enough to be seen 
on an X-ray. Second, the majority of patients had a monoarticular or oligoarticular phenotype 
with arthritis of other, bigger joints, such as the knee, shoulder and ankle. Progression in these 
would be missed in a PsA-modified Sharp-van der Heijde score. In this scoring method, the 
small joints of hand and feet are assessed for joint space narrowing and erosions, but not 
for progression in bigger joints. Third, joint space narrowing and erosions are scored, while 
new bone formation might be a more appropriate sign of structural progression specifically in 
PsA.21, 22 However, we regard it unlikely that this explains the low progression rates. Though not 
part of the scores we used for the analysis, we did register new bone formation and found that 
it often occurred simultaneously with radiological progression. 
 Though not analysed as such, the patterns of restoring of disease burden and 
productivity in the late MDA group provide insight in how patients compensate disease activity. 
In the patients who achieved MDA late, work productivity is restored months before the disease 
burden is resolved and even before MDA is actually achieved. This might be interpreted as 
follows: restoring work productivity is a priority to patients, and loss of work productivity can 
be interpreted as a sign that the extent or the duration of high disease activity can no longer 
be compensated by coping mechanisms. This should be prevented, because employment 
is difficult to restore once lost.23 It is another argument why active disease should be treated 
early, in order to maintain participation and reduce societal impact of disease. 
PERFORMANCE OF DISEASE ACTIVITY MEASURES
Our analysis of performance of different disease activity measures really comes down to the 
question: what is disease activity of PsA? PsA is an inflammatory disease and disease activity is 
the extent to which symptoms resulting from inflammation are present. We have many ways of 
assessing symptoms of PsA, though many of them are heavily debated as discussed in previous 
sections. The measures MDA, GRAppa Composite ScorE (GRACE), Psoriatic ArthritiS Disease 
Activity Score (PASDAS), and Composite Psoriatic Disease Activity Index (CPDAI) include 
disease activity in domains other than arthritis (i.e. psoriasis and enthesitis), and also some 
aspects of patient-reported impact of disease with questionnaires about disability (i.e. the 
Health Assessment Questionnaire) or HRQOL (i.e. Short Form-36, : PsA-specific Quality of Life). 
MDA and the continuous measures PASDAS and GRACE had the best relation with evolvement 
of burden of disease, functioning and productivity in the first year after diagnosis, as compared 
with more articular measures such as Disease Activity Score 28 (DAS28) and Disease Activity 
index for PSoriatic Arthritis (DAPSA). 
 The concept of treat-to-target (T2T) has been adopted from treatment of other 
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chronic conditions, such as diabetes: instead of the same treatment for all patients, treatment 
is intensified if the target of Hb1Ac has not been met.24 Subclinical, chronic exposure to high 
glucose levels leads to complications in diabetes.25, 26 The translation to PsA then is: chronic 
inflammation leads to structural damage and needs to be controlled tightly. In PsA, however, 
the risk of structural damage as a result of inflammation cannot be determined based on one 
symptom or a single laboratory test. Also, PsA activity is not subclinical and treatment is not 
only given to prevent long-term structural damage, but also to improve current functioning. 
For these reasons, composite disease activity measures have been developed, in which 
disease activity as measured with different manifestations and patient-reported outcomes 
(PROs) are combined in a single measure. There is no consensus on what to include in this 
composite disease measure, mainly because the inclusion of manifestations of enthesitis, 
dactylitis, spondylitis, and psoriasis has been debated. It has not been established that 
patients with these manifestations have a higher risk of developing structural damage, as is 
the case for the manifestation of arthritis. For example, psoriasis patients – with or without PsA 
– in the care of dermatologists do not receive T2T with prespecified targets, as is common in 
rheumatology. There is no consensus on a definition of severe psoriasis is, though a Psoriasis 
Area and Severity Index (PASI) above 10 or 12, or a severe impact on HRQOL is a commonly 
used definition.27, 28 
 We have shown that measures including multiple manifestations, such as the GRACE, 
PASDAS and MDA, are a better reflection of disease burden and have superior responsiveness 
and longitudinal validity in the first year after diagnosis. The impact of disease is not completely 
captured by DAPSA and DAS28. Related to this, we have also shown that manifestations 
beside arthritis lower HRQOL at time of diagnosis. Rheumatologists need to be aware of this 
and they should take it into account when choosing treatment. With respect to psoriasis, they 
should consult a dermatologist when necessary. Whether PASDAS, GRACE and MDA are also 
superior in determining outcomes after 1 year and at predicting structural damage remains to 
be investigated in a study with longer follow up. It will show whether high disease activity in 
domains other than arthritis needs to be controlled as well in order to prevent future disability. 
In that study it would also be possible to investigate whether the measures can be simplified 
without losing its ability to predict current and future functioning. A simpler measure is more 
likely to be incorporated in clinical practice. 
 Besides including multiple manifestations, the measures PASDAS, GRACE and MDA 
also include more PROs than DAS28 or DAPSA. Adding patient-reported disease burden to 
objective measures of disease activity is a more personalized measurement: all aspects of 
disease are assessed in a total score of disease activity, incorporating also how much the 
patient suffers from these aspects of disease. This could aid in choosing the appropriate type of 
treatment. In the analysis of these composite measures related to outcomes, two considerations 
need to be taken into account. First, the objectivity of including PROs in a disease measure has 
General discussion
1 2 9
8
been debated. PROs are more likely to be affected by for example comorbidities,29-31 capturing 
more than disease activity alone. It is however not true that only PROs have this problem: a 
swollen or tender joint could be a symptom of osteoarthritis, increased acute phase reactants 
can have many other causes than PsA, and radiographic damage of DIP joint especially can 
also be caused by osteoarthritis.32 Also, in RA it is known that the best predictor of flare or 
achieving low disease activity are PROs,33, 34 suggesting these are more sensitive than for 
example a swollen joint count. Luckily, the treating physician is tasked with the interpretation 
of a disease activity measure before prescribing treatment. Second, it should be noted that the 
outcomes of our analysis contains some circular reasoning: something that combines X and 
Y is expected to be related to X in the long term. The true value of different disease measures 
therefore needs to be studied in interventional studies: do treatment and outcomes improve 
if treatment is chosen based on PASDAS or GRACE, rather than usual care?
GENERAL CONSIDERATIONS
Some sources of bias have been discussed in the previous sections if they were specific to the 
research question discussed. Regarding generalisability, measurement error, and missing data, 
some general considerations in the interpretation of the results in this thesis are discussed 
below. 
Generalizability
The patients in our studies that investigated ultrasound of the entheses were consecutive PsA 
patients attending the outpatient clinic of secondary hospitals and a tertiary hospital. Patients 
were not selected based on their risk of enthesitis, reflected also in the absence of enthesitis at 
clinical examination and on ultrasound in some patients. We aimed to study the spectrum of 
entheseal abnormalities in an average PsA patient, to conclude which changes were specific 
to PsA and which were not. We believe our results are generalizable to PsA patients receiving 
outpatient care by a rheumatologist, though the high percentage of biological use suggests 
we selected patients with slightly more severe disease. Our results cannot be extrapolated to 
patients who are suspected of having enthesitis. 
 All patients with a new diagnosis of PsA, as defined by the expert opinion of the 
treating rheumatologist, are eligible to participate in the DEPAR study. It should be noted 
that not all patients with a new diagnosis participated in the study. Taking this into account, 
in contrast with observational studies of established PsA patients or clinical trials, our study 
population represents PsA patients in daily clinical care. Fulfilling classification criteria for PsA 
was not a requirement, though many patients happened to fulfil the CASPAR classification 
criteria. At the expense of slightly less comparability with other studies, our findings of disease 
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burden and disease activity can be translated to patients with a new diagnosis. 
Measurement error
Disease activity was determined based on data collected by research nurses, which might 
differ from the assessment of the physician who actually prescribed treatment. Some patients 
could have been classified as having active disease according to the research nurse, but might 
be considered in low disease activity according to the physician. In that case, the disease was 
recorded as active, whereas treatment was not intensified for these patients. The systematic 
overestimation of disease activity by nurse or underestimation by physician (and vice versa) 
will lead to bias if patients of one physician have worse HRQOL and productivity outcomes. 
For example if the physician does not ask patients with mild disease to participate. This can be 
corrected for in a mixed model, by adding another level of correlation (i.e. treating physician). 
We did however not have the power to do so with the many physicians and sometimes only 
a few patients per physician. We encouraged physicians to include all patients with a new 
diagnosis, and we suspect patients physicians are consistent in their treatment of PsA. 
Missing Data
In the ideal study, all patients included in the study complete their follow up, they do not 
miss any study visits, they have all their clinical data collected at each study visit, and they 
complete all their questionnaires. In the real world however, we are faced with the problem of 
missing data, which could be a source of bias in our analyses . Conceptually, there are 3 forms 
of missing data: missing completely at random (MCAR), missing at random (MAR), and missing 
not at random (MNAR).35 Data are MCAR if missingness is unrelated to what we observed and 
what we could not observe because of the missingness: an example of MCAR we observed in 
the DEPAR study was that some patients were not able to visit the research nurse because the 
rheumatology department was relocating. This is completely unrelated to disease activity or 
the outcomes of the patient. The data we have is a random sample of the complete data we 
would have, which leads to less efficiency but not to bias. 
 Data are MAR if missingness is related to what we observed, but not to what we 
could not observe; for example, patients with a lower baseline disease activity are more often 
discharged from care by their physician and less likely to complete the study. We recorded the 
baseline disease activity and if we correct for that in a mixed model analysis, the results of the 
analysis are unbiased. In our analysis of time to MDA and outcomes of HRQOL and productivity 
we corrected for baseline disease activity factors, as well as age and gender, thereby producing 
valid results if missingness of data is related to any of these factors. There is however still a 
chance of bias of the estimated effect of time to MDA on outcomes, if our missing data are 
MNAR. 
 Data are MNAR if the missingness is related to something we did not observe: for 
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example, patients with worse HRQOL were so ill that they were less likely to complete their 
questionnaire about HRQOL, even after we corrected for baseline factors. Since we cannot 
test an association with something we do not know, there is no way to test whether data is 
MNAR. The strength of the conclusions can be assessed by making different assumptions 
about the missing data and testing whether the conclusions are altered. We did not perform a 
formal sensitivity analysis, but we are able to speculate about the consequences of this MNAR. 
Based on the reasons patients provided for stopping with the study, we suspect patients drop 
out because of two main reasons.  Some are doing very well, are discharged from care, and 
have difficulty combining visits to the research nurse with work. Their outcomes are likely to 
be better those of patients without missing data. Others suffer from severe comorbidities or 
have had other life events, whose outcomes are likely to be worse. We deem it most likely 
that the first group are mostly patients achieving MDA early (i.e. patients early in MDA are 
discharged from care within the first year) and the second group are mostly patients not in 
MDA (i.e. patients suffering from severe comorbidities or life events are not in MDA). In that 
case the effect between time to MDA and outcomes was an underestimation of the true effect. 
In our comparison of performance, this mechanism of missing data might bias the relation 
between other disease activity measures and outcomes as well, but the bias will be the same 
for all measures. Hence, the performance of disease measures relative to each other will not be 
biased.  
RECOMMENDATIONS FOR CLINICAL PRACTICE
Based on the new insights provided in this thesis and discussed above, and in light of their 
considerations, we have the following recommendations for clinical practice for each aim.
Ultrasound abnormalities of the entheses
For the purpose of confirming a suspicion of enthesitis on the enthesis-level, 
ultrasound of the entheses should be used with caution, given the many changes 
also found in healthy adults.
Burden of disease at time of diagnosis
More attention to manifestations of PsA other than arthritis is needed, as burden of 
disease is determined by enthesitis and chronic back pain as well.
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Time to minimal disease activity
Outcomes improve if patients achieve low disease activity, and therefore treatment 
should be aimed at achieving a state of low disease activity.
A third of patients is not able to achieve low disease activity in the first year after 
diagnosis and as a result these patients continue having a high impact of disease. 
These patients might benefit from earlier escalation of therapy.
Patients achieving MDA late in the first year are able to reach a similar level of 
functioning as patients achieving MDA early, suggesting that the window of 
opportunity has not yet closed in the first 3 months after diagnosis.
Performance of disease activity measures
Articular measures DAS28 and DAPSA should not be used as a target in T2T for 
PsA, as they underestimate impact of disease. It could potentially lead to under 
treatment of patients with residual active disease.
As an alternative to DAPSA, the disease measures GRACE or PASDAS could be used 
to measure disease activity on a continuous scale.
RECOMMENDATIONS FOR FUTURE RESEARCH
To further aid clinical decision making, more research is needed and the following 
recommendations are considered the most relevant with respect to measuring disease activity 
and outcomes in early PsA.  
Ultrasound abnormalities of the entheses
A better reference frame of the ‘normal’ enthesis is needed: more research of the 
entheses of healthy volunteers and factors associated with changes of the entheses 
on ultrasound and other imaging techniques should be carried out.
General discussion
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The effects of physical activity and medication on the entheses of patients with 
PsA should be studied in longitudinal, prospective studies. This could be done in 
interventional studies, in which patients suspected of enthesitis are randomized 
to receive an intervention (either medical or physical therapy) or usual care, and 
monitored with ultrasound. It would show whether ultrasound is able to identify 
those patients most likely to respond to therapy.
Patients with PsA have on average more signs of structural damage at the entheses, 
which is possibly a result of longstanding inflammation in the enthesis. Instead of 
relating abnormalities of one enthesis to enthesitis, a total score such as the MASEI 
might be used. The prognostic purposes of the MASEI should be studied in a cohort 
study of psoriasis patients, to test whether MASEI is able to predict incidence of PsA 
in a psoriasis population.
Burden of disease at time of diagnosis
The effect of treatment on enthesitis, dactylitis and spondylitis should be studied 
in patients who have this as primary manifestation. In the currently available data, 
effects on manifestations besides arthritis were secondary outcomes, which were 
studied in a  population that had a predominant phenotype of polyarthritis.
The association between each manifestation and  burden of disease should be 
studied longitudinally, to see whether manifestations other than arthritis are 
treatable and whether their impact on disease burden is reversible or resistant to 
treatment.
Time to minimal disease activity
In patients who were able to achieve MDA in the first year, similar levels of functioning 
were achieved. To be sure the therapeutic window has not closed in the first 3 
months, more research regarding long-term outcomes is needed. These include 
effects on disease activity and outcomes after one year, as well as the radiological 
progression after 1 year.
Regarding patients who are not able to achieve MDA in the first year, we need to 
know whether these patients will get in MDA after 1 year or not at all. If they are 
able to achieve MDA, the reversibility on the same outcomes as mentioned before 
should be assessed.
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As MDA is worthwhile to achieve, it is relevant to know whether we can predict the 
time to MDA. The ability of baseline disease activity, age, gender, and perhaps even 
factors such as biomarkers to predict time to MDA at time of diagnosis needs to be 
tested. If we know which patients will be less likely to achieve MDA soon, we could 
potentially improve outcomes for these patients by monitoring more frequently 
and escalating treatment more quickly. 
Performance of disease activity measures
We have shown that disease activity measures differ in their assessment of HRQOL 
and functioning in the first year after diagnosis. To choose the best measure for use 
in clinical practice, disease activity measures need to be compared in their ability to 
predict radiologic progression, and disability beyond 1 year after diagnosis.
Some disease activity measures are not likely to be incorporated in current clinical 
practice, as they require too much information in their calculation. It needs to be 
tested whether some components are not needed to predict current and long-term 
functioning, and disease progression.
The efficacy of T2T with the best target - based on analyses of observational 
research - needs to be shown in a randomized clinical trial. In this trial, patients 
in current usual care should be randomized to receive either usual care, T2T with 
DAS28, or T2T with the best target for PsA. The primary outcome should be disability 
or HRQOL. Secondary outcomes should include radiographic progression, adverse 
events, and cost-effectiveness.
General discussion
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SUMMARY
Psoriatic Arthritis (PsA) is a heterogeneous disease, characterized by manifestations of 
peripheral arthritis, dactylitis, enthesitis, spondylitis, and psoriasis. Patients with PsA experience 
the impact of disease as loss of functional ability, decreased health-related quality of life 
(HRQOL) and loss of productivity. Treatment is aimed at preventing these consequences. It is 
recommended that treatment is given as early as possible,  with all manifestations taken into 
account, and in a treat-to-target strategy. In a treat-to-target strategy, treatment is intensified 
if a certain target – a composite disease activity measure – has not been achieved. Good 
measures of disease activity are needed to improve outcomes for patients with PsA. For this 
purpose, more information is needed on disease activity and outcomes early in the disease 
course. These are studied in the Dutch southwest Early Psoriatic Arthritis cohoRt (DEPAR) and 
related sub-studies. 
 This thesis aims to investigate the following four aspects of disease activity and 
outcomes in early PsA: ultrasound abnormalities of the entheses, burden of disease at time of 
diagnosis and its relation with disease manifestations, the relation between time to minimal 
disease activity and outcomes, and the performance of disease activity measures. 
Ultrasound abnormalities of the entheses
In Chapter 2, we compare the prevalence of ultrasound abnormalities at the entheses in 
patients with a new diagnosis, in patients with established disease, and in young, healthy 
volunteers aged 20 to 30 years. Participants were included consecutively, irrespective of 
complaints suggestive of enthesitis. In healthy volunteers, the entheses around the knees 
often had increased thickness, and also a mild power Doppler (PD) signal often occurred. 
We therefore excluded thickness of knee entheses from the Madrid Sonographic Enthesitis 
Index (MASEI) and recoded PD signal, resulting in a modified MASEI score. The modified MASEI 
showed better discrimination between PsA patients and healthy volunteers. No differences in 
the modified MASEI scores were observed between patients with a new diagnosis and patients 
with established disease. 
 The modified MASEI was studied in a larger population of established PsA patients 
and older healthy volunteers (aged 35 to 60 years). Also within the established PsA population, 
we studied which factors were associated with ultrasound abnormalities of the entheses. 
These results are displayed in Chapter 3. The structural components of the modified MASEI 
(i.e. calcifications, erosions, and structural changes) were again significantly higher in PsA 
patients than in healthy volunteers. The inflammatory components of the modified MASEI 
(i.e. increased thickness except knee entheses, bursitis, and PD signal) however did not differ 
significantly. Within PsA patients with established disease, higher age and current use of 
biologicals were associated with a higher inflammatory modified MASEI score. Patients who 
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reported avoiding physical activities had significantly lower modified MASEI scores. More 
structural abnormalities of the entheses were seen in older PsA patients. 
Burden of disease at time of diagnosis
The burden of disease at time of diagnosis of PsA, as measured with HRQOL, is studied in 
Chapter 4. HRQOL is significantly lower in PsA patients compared with the general population. 
This is seen in both the mental and physical aspects of HRQOL, with a higher impact on the 
physical aspects. In this chapter, we also study which manifestations are responsible for the 
burden of disease at time of diagnosis. Besides having more tender joints, both enthesitis 
at clinical examination – present in 46% of patients – and presence of chronic back (39% of 
patients) were associated with a higher burden of disease.  Given these, more swollen joints, 
presence of dactylitis and more severe psoriasis did not add to the burden of disease. 
Time to minimal disease activity
The window of opportunity in PsA is studied in Chapter 5. We investigated the time patients 
needed to achieve a certain target of low disease activity for the first time in the first year, using 
Minimal Disease Activity (MDA). Of all patients with a new diagnosis of PsA, 32% were able to 
achieve MDA within 3 months (early MDA) and another 26% within the first year after diagnosis 
(late MDA). The exact time to MDA could not be determined in 8% and 33% was never in MDA in 
the first year after diagnosis. The outcomes of HRQOL and productivity significantly improved 
once MDA was achieved. Patients in MDA early were significantly longer in MDA during the first 
year after diagnosis, and as a result their outcomes throughout the first year were significantly 
better than those of patients late in MDA or never in MDA in the first year. The patients late in 
MDA had worse outcomes throughout the first year, but were able to reach a similar level of 
HRQOL and productivity at 1 year after diagnosis. Impact on outcomes in patients never in 
MDA in the first year remained as high as at time of diagnosis. No differences were observed in 
radiographic progression between the 3 groups. 
Performance of disease activity measures 
In Chapter 6, the validity of 2 disease activity measures, recommended for use in clinical 
practice by an international task force, is tested: the measures MDA and Disease Activity index 
for PsA (DAPSA). We tested whether patients fulfilled definitions of MDA and DAPSA low disease 
activity (DAPSA-LDA, i.e. DAPSA ≤ 14), and within these different definitions of low disease 
activity we compared the burden of disease in the domains body functions and activity. One 
year after diagnosis and receiving usual care, 48% of patients was in MDA and 74% was in 
DAPSA-LDA. MDA was a stricter definition of low disease activity and burden of disease was 
significantly lower in patients in MDA than in patients in DAPSA-LDA. In patients with complete 
data on both MDA and DAPSA-LDA, 46% had achieved both MDA and DAPSA-LDA and 25% had 
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achieved neither definition of low disease activity. Only 2 (1%) patients were in MDA and not in 
DAPSA-LDA, while  29% of all patients were in DAPSA-LDA but not in MDA. The latter group of 
patients who had achieved DAPSA-LDA, but not MDA, had worse outcomes of body functions 
and activity than patients who had achieved both DAPSA-LDA and MDA. 
 The responsiveness and longitudinal validity of all available disease activity measures 
for PsA are compared in Chapter 7. These measures were disease activity score 28 (DAS28), 
DAPSA, Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity 
Score (PASDAS), GRAppa Composite scorE (GRACE) and MDA. Responsiveness of continuous 
measures (i.e. all but MDA) was tested using the effect size, standardized response mean, 
and discrimination between different general health states. The effect size and standardized 
response mean of the first year after diagnosis were highest for PASDAS and lowest for DAPSA. 
Differences in general health could best be discriminated by GRACE and PASDAS. DAS28 and 
CPDAI were not able to discriminate between patients reporting stable general health and 
those reporting worsening of general health. In order to compare longitudinal validity of each 
measure, the longitudinal evolvement relative to the longitudinal evolvement of outcomes 
of HRQOL, productivity and disability was analyzed for all  measures. This was done by 
comparing the fit of mixed models with different disease activity measures as variables. The 
longitudinal evolvement of HRQOL (using the Short Form-36 Physical Component Summary) 
and work productivity was best captured with GRACE, PASDAS and MDA. For the outcome 
disability as measured with the HAQ, the association was highest with GRACE, MDA and CPDAI. 
Summarizing, in terms of both responsiveness and longitudinal validity, PASDAS, GRACE and 
MDA were superior to DAS28, DAPSA and CPDAI. 
 
In Chapter 8,  the results for each of the four aims are summarized and discussed, and general 
considerations with respect to generalizability and missing data are given. This thesis ends 
with recommendations both for clinical practice and for future research. 
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SAMENVATTING
Artritis psoriatica is een auto-immuunziekte, waarbij ontstekingscellen van het afweersysteem 
zich richten tegen de cellen van het eigen lichaam. Hierdoor ontstaat er een chronische 
ontsteking. Zo’n ontsteking kan bij artritis psoriatica ontstaan in: de gewrichten (artritis), de 
peesaanhechtingen (enthesitis), de rug (spondylitis), de gehele vinger of teen (worstteen of 
worstvinger: dit wordt dactylitis genoemd), de huid (psoriasis) en de nagels (nagelpsoriasis, 
zie ook Figuur 1 van de introductie). Patiënten hebben onder andere last van pijn, stijfheid 
en vermoeidheid, waardoor ze minder goed kunnen functioneren en een lagere kwaliteit van 
leven hebben dan gezonde mensen. In de meeste gevallen krijgen patiënten eerst psoriasis.   
 Bij psoriasis is er sprake van een chronische ontsteking die gericht is tegen de cellen 
in de huid. Door deze ontsteking gaan de huidcellen veel sneller delen dan normaal en zo 
ontstaan er rode, schilferende plekken op de huid. Deze plekken worden psoriasisplekken 
genoemd. Deze kunnen jeuken en pijn doen, maar zijn niet besmettelijk. Een deel van de 
patiënten met psoriasis krijgt om nog onbekende reden ook een chronische ontsteking van 
het bewegingsstelsel.  Deze patiënten krijgen dan de diagnose artritis psoriatica. Geschat 
wordt dat 6-42% van de patiënten met psoriasis uiteindelijk artritis psoriatica zal ontwikkelen, 
meestal op een leeftijd tussen de 30 en 50 jaar. Het komt even vaak voor bij mannen als bij 
vrouwen. In totaal heeft 0,19% van de bevolking in Europa artritis psoriatica. De diagnose 
artritis psoriatica wordt gesteld door een reumatoloog, op basis van de klachten van de 
patiënt, het lichamelijk onderzoek, de ontstekingswaarden in het bloed en op basis van de 
afwijkingen aan de gewrichten op röntgenfoto’s. 
 Patiënten met artritis psoriatica worden behandeld met reumaremmers, die de 
ontstekingscellen afremmen zodat ook de chronische ontsteking verdwijnt. Het is belangrijk 
dat de ontsteking snel onderdrukt wordt en onderdrukt blijft, zodat er geen blijvende schade 
ontstaat aan bijvoorbeeld de gewrichten. Er zijn verschillende reumaremmers beschikbaar, 
die allemaal net iets anders werken en bovendien niet bij iedere patiënt even goed werken. Na 
het starten van de therapie worden patiënten regelmatig door hun reumatoloog gecontroleerd 
om te kijken of er bijwerkingen optreden en of de ontsteking goed genoeg onderdrukt is. Dat 
controleren van de onderdrukking van de ontsteking wordt gedaan met een maat voor de 
ziekteactiviteit. In deze maat worden verschillende metingen gecombineerd tot één getal. Als 
dit getal te hoog is (wat wil zeggen dat de ziekteactiviteit hoog is), wordt de therapie aangepast. 
 In dit proefschrift is het meten van de ziekteactiviteit en uitkomsten (zoals ziektelast, 
kwaliteit van leven en productiviteit op werk) van patiënten met vroege artritis psoriatica 
onderzocht. Het doel was om de volgende 4 aspecten te onderzoeken: 
• het echografisch onderzoek van de peesaanhechtingen
• de ziektelast op het moment van diagnose en het effect van verschillende symptomen op 
die ziektelast
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• de relatie tussen de tijdsduur totdat een lage ziekteactiviteit was bereikt en uitkomsten 
• het vergelijken van verschillende maten voor het meten van ziekteactiviteit
 Dit onderzoek is uitgevoerd bij deelnemers aan de DEPAR studie, wat staat voor Dutch 
southwest Early Psoriatic Arthritis cohoRt. Patiënten werden gevraagd mee te doen, net nadat 
ze de diagnose artritis psoriatica hadden gekregen van hun reumatoloog. In het eerste jaar 
na de diagnose bezochten patiënten een onderzoeksverpleegkundige die de ziekteactiviteit 
registreerde. Ook werden patiënten gevraagd vragenlijsten in te vullen over onder andere de 
ziekteactiviteit, de kwaliteit van leven,  hun functioneren en hun werk. Bij ieder bezoek liet de 
patiënt bloed prikken zodat de ontstekingswaarden in het bloed gemeten konden worden en 
werden er jaarlijks röntgenfoto’s van handen en voeten gemaakt om eventuele schade aan de 
gewrichten op te sporen.  
Het echografisch onderzoek van de peesaanhechtingen
Een chronische ontsteking van de peesaanhechtingen (enthesitis) kan klachten geven die 
lijken op normale klachten van de pezen zelf. Deze normale klachten komen veel voor in de 
algemene bevolking en ontstaan vaak op de leeftijd waarin meestal ook artritis psoriatica 
ontstaat: 30 tot 50 jaar. Met echografie kunnen de peesaanhechtingen in beeld gebracht 
worden, om te kijken of er tekenen van ontsteking zijn. Welke afwijkingen op de echo echter 
specifiek zijn voor artritis psoriatica is nog niet goed onderzocht.
 In hoofdstuk 2 is onderzocht welke afwijkingen van de peesaanhechtingen 
gezien worden bij artritis psoriatica op het moment van de diagnose. Dit werd vergeleken 
tussen patiënten die al wat langer de ziekte hadden en met jonge, gezonde volwassenen. 
De peesaanhechtingen van deze groep jonge, gezonde vrijwilligers zijn naar verwachting 
volgroeid, maar hebben nog geen schade opgelopen. Er waren 2 opvallende bevindingen bij 
gezonde vrijwilligers. Bij deze groep was de dikte van de peesaanhechtingen rond de knie 
vaak hoger dan de normaalwaarden. Ook waren er tekenen van verhoogde doorbloeding te 
zien in deze peesaanhechtingen, wat als een teken van ontsteking gezien zou kunnen worden 
(zie ook Tabel 2 van hoofdstuk 2). In vergelijking met de peesaanhechtingen van patiënten 
met artritis psoriatica was er wel een verschil in intensiteit van het doorbloedingssignaal op 
echografie. Daarom is er een score gegeven aan de ernst van het signaal in plaats van de aan- 
of afwezigheid van het doorbloedingssignaal te registeren. Deze twee bevindingen hebben 
geleid tot een aanpassing van de totaalscore van de echoafwijkingen: bij het optellen van alle 
afwijkingen op de echobeelden is de dikte van de kniepezen niet meegenomen en is gebruik 
gemaakt de gradering in intensiteit van doorbloedingssignaal. Deze nieuwe scoringsmethode 
maakte een beter onderscheid tussen de peesaanhechtingen van jonge, gezonde volwassenen 
en patiënten met artritis psoriatica. Er was geen verschil in deze score tussen patiënten die net 
de diagnose hebben gehad en patiënten die al wat langer de ziekte hadden.
 Deze nieuwe score werd vervolgens toegepast in een nieuwe groep met artritis 
Samenvatting
1 4 5
psoriatica patiënten en vergeleken met wat oudere gezonde vrijwilligers. Daarnaast is 
er ook gekeken welke factoren van invloed zijn op het hebben van afwijkingen aan de 
peesaanhechtingen bij patiënten. De resultaten hiervan staan beschreven in hoofdstuk 3. De 
afwijkingen op de echografie kunnen ingedeeld worden in 2 groepen: een actieve ontsteking of 
structurele schade. De totaalscore voor de actieve ontsteking verschilde niet tussen de gezonde 
vrijwilligers en patiënten met artritis psoriatica, wat aangeeft dat deze afwijkingen niet specifiek 
bij artritis psoriatica horen. Patiënten met artritis psoriatica hadden wel meer structurele 
schade aan de peesaanhechtingen. De patiënten met een hogere leeftijd – en dus een langere 
ziekteduur – hadden meer actieve ontstekingen en structurele schade dan de groep gezonde 
vrijwilligers. Als patiënten aangaven dat ze fysieke activiteit vermeden vanwege de angst om 
klachten te krijgen, bleken deze patiënten minder tekenen van een actieve ontsteking aan de 
peesaanhechtingen te hebben. Patiënten die een specifiek type reumaremmers gebruikte, de 
biologicals, hadden meer actieve ontstekingen aan de peesaanhechtingen.
De ziektelast op het moment van diagnose
Er is nog weinig bekend over de ziektelast die patiënten in een vroeg stadium van de ziekte 
hebben en welke symptomen nu precies zorgen voor die ziektelast. Artritis psoriatica is een 
heterogene ziekte, wat inhoudt dat er veel verschillen zitten in de symptomen die patiënten 
kunnen hebben. In hoofdstuk 4 staat beschreven wat de kwaliteit van leven van patiënten is 
vlak nadat ze gediagnosticeerd zijn met artritis psoriatica en nog voor ze begonnen zijn met 
de behandeling van de ziekte. Vergeleken met de algemene Nederlandse bevolking was de 
kwaliteit van leven een stuk lager bij patiënten met artritis psoriatica en dit effect was sterker 
voor de fysieke aspecten (zoals pijn en algehele gezondheid) dan voor de mentale aspecten van 
kwaliteit van leven (zoals sociaal functioneren en vitaliteit, zie ook Figuur 1 van hoofdstuk 4). 
Patiënten hadden vaak meerdere symptomen en het effect van ieder symptoom onafhankelijk 
van de andere symptomen op de kwaliteit van leven is geanalyseerd. Het hebben van meer 
pijnlijke gewrichten, meer ontstoken peesaanhechtingen en het hebben van chronische 
lage rugklachten was geassocieerd met een slechtere kwaliteit van leven. Daarnaast was het 
hebben van ernstigere psoriasis, meer gezwollen gewrichten, of het hebben van een worstteen 
of -vinger (dactylitis) niet van invloed op de kwaliteit van leven. 
De tijdsduur tot lage ziekteactiviteit
Patiënten met artritis psoriatica krijgen reumaremmers om de chronische ontsteking te 
onderdrukken. Het doel van de behandeling met deze medicijnen is de ziekte een zo klein 
mogelijk effect te laten hebben op het functioneren en de kwaliteit van leven en het voorkomen 
van blijvende schade. De relatie tussen het behalen van een lage ziekteactiviteit en de kwaliteit 
van leven en werkproductiviteit zijn onderzocht in hoofdstuk 5. Ook is onderzocht hoe lang 
het duurde voordat patiënten een lage ziekteactiviteit hadden, en of het uitmaakte voor de 
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kwaliteit van leven en werkproductiviteit als het langer duurde voordat een lage ziekteactiviteit 
werd bereikt. Ongeveer een derde van de patiënten had binnen 3 maanden voor het eerst 
een lage ziekteactiviteit, en weer een derde van de patiënten later in het eerste jaar. De rest 
van de patiënten kon in het eerste jaar nadat ze de diagnose kregen geen lage ziekteactiviteit 
behalen. Op het moment dat patiënten een lage ziekteactiviteit hadden, trad er een herstel 
van kwaliteit van leven en werkproductiviteit op. Omdat de patiënten die vroeg een lage 
ziekteactiviteit bereikten hier eerder van konden profiteren, waren hun uitkomsten gemiddeld 
genomen over het eerste jaar beter. De uitkomsten van patiënten die niet na 3 maanden, maar 
wel binnen het eerste jaar voor het eerst een lage ziekteactiviteit hadden bereikt, werden later 
beter: een jaar na diagnose was er geen verschil meer tussen patiënten die vroeg of laat een 
lage ziekteactiviteit hadden behaald. Bij de patiënten die geen lage ziekteactiviteit konden 
behalen, bleef de ziekte een grote impact op hun kwaliteit van leven en werk houden (zie ook 
Figuur 1 van hoofdstuk 5). In de 3 onderzochte groepen was er geen verschil in de verergering 
van de schade aan de gewrichten die opgelopen was in dat eerste jaar. 
Vergelijken van maten van ziekteactiviteit
Om de behandeling optimaal af te stemmen op de patiënt moet de activiteit van de ziekte goed 
gemeten worden. Er zijn verschillende maten voor de ziekteactiviteit beschikbaar bij artritis 
psoriatica. Deze maten verschillen onderling in: het meetellen van het aantal gewrichten, 
andere symptomen dan gewrichtsontsteking (de ernst van de psoriasis, ontstekingen aan de 
peesaanhechtingen of rug en het hebben van een worstteen of -vinger), ontstekingswaarden 
in het bloed en de soort vragenlijsten (zie ook Tabel 1 van de introductie). Het is niet makkelijk 
om de verschillende maten van ziekteactiviteit met elkaar te vergelijken. Dit komt doordat 
er geen referentiewaarde bestaat die de ‘waarheid’ weergeeft en waarmee de andere maten 
vergeleken kunnen worden. 
 Twee maten zijn in recente literatuur aanbevolen om te gebruiken in de klinische 
praktijk bij het behandelen van patiënten met artritis psoriatica: de MDA (Minimal Disease 
Activity) en de DAPSA (Disease Activity index for Psoriatic Arthritis). In hoofdstuk 6 is 
onderzocht welke maat het beste de ziekteactiviteit meet, door de ziektelast van patiënten 
die aan de definitie MDA voldeden te vergelijken met de ziektelast van patiënten die aan 
de definitie DAPSA voor lage ziekte activiteit voldeden. Hiervoor zijn gegevens gebruikt van 
patiënten een jaar na hun diagnose en behandeling bij de reumatoloog. Voor de uitkomst 
ziektelast werd gekeken naar lichamelijke pijn, vermoeidheid, fysiek functioneren en fysieke 
beperkingen. Patiënten rapporteerden dit door middel van vragenlijsten. De ziekteactiviteit 
moest lager zijn om aan MDA te voldoen dan aan DAPSA lage ziekteactiviteit: 48% van de 
patiënten voldeed aan de MDA definitie, vergeleken met 74% van de patiënten volgens de 
DAPSA lage ziekteactiviteit definitie. Als patiënten aan de MDA voldeden, hadden ze meestal 
ook lage ziekteactiviteit volgens de DAPSA: 46% van de patiënten voldeed namelijk aan beide 
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definities. Verder voldeed 29% alleen aan lage ziekteactiviteit volgens de DAPSA, 1% alleen de 
MDA en 25% van de patiënten voldeed aan geen van beide definities van lage ziekteactiviteit. 
Patiënten die aan de definitie van MDA voldeden hadden een lagere ziektelast dan patiënten die 
lage ziekteactiviteit hadden volgens de DAPSA. De patiënten die alleen een lage ziekteactiviteit 
hadden volgens de DAPSA, hadden een lagere ziektelast dan patiënten die daar niet aan 
voldeden, maar nog niet zo laag als patiënten ervaarden die aan beide definities voldeden (zie 
ook Figuur 1, 2 en 3 in hoofdstuk 6 en Figuur 1 en 2 in het supplement bij hoofdstuk 6).
 Een vergelijking van alle maten van ziekteactiviteit die er momenteel beschikbaar zijn 
voor artritis psoriatica staat beschreven in hoofdstuk 7. Wederom werden MDA en DAPSA 
vergeleken, maar daarnaast werden ook de DAS28 (disease activity score 28), de CDPAI 
(Composite Psoriatic Disease Activity Index) de PASDAS (Psoriatic ArthritiS Disease Activity 
Score), en de GRACE (GRAppa Composite scorE) onderzocht. Allereerst is onderzocht welke 
maat het beste veranderingen in de ziekteactiviteit kon meten. De verandering in het eerste jaar 
van de score zelf was het hoogst voor de PASDAS, en het laagst voor de DAPSA (zie ook Figuur 
1 van hoofdstuk 7). Patiënten werd ook gevraagd of ze veranderingen in algehele gezondheid 
ten opzichte van 3 maanden geleden konden beoordelen. Hen werd gevraagd of hun algehele 
gezondheid nu ‘veel beter’, ‘wat beter’, ‘ongeveer hetzelfde’, ‘wat slechter’ of ‘veel slechter’ was. 
Deze 5 groepen patiënten konden het beste onderscheiden worden op basis van het verschil 
in PASDAS-score en GRACE-score. De patiënten konden het slechts onderscheiden worden op 
basis van hun CPDAI-score (zie ook Figuur 2 van hoofdstuk 7). Daarnaast is onderzocht welk 
verloop van de ziekteactiviteit over het eerste jaar het beste overeenkwam met het verloop in 
de ziektelast die patiënten rapporteerden. Voor de ziektelast werden de kwaliteit van leven, de 
werkproductiviteit en fysieke beperkingen onderzocht. De GRACE, PASDAS en MDA hadden de 
grootste associatie met de kwaliteit van leven en werk, en de GRACE, MDA en CPDAI hadden 
de grootste associatie met fysieke beperkingen. Alle analyses samen genomen, waren de 
PASDAS, GRACE en MDA beter in het meten van de ziekteactiviteit dan de DAS28, DAPSA en 
CPDAI. 
Hoofdstuk 8 bevat een algemene discussie waarin de 4 onderzoeksdoelen besproken 
worden, welke bedenkingen meegenomen moeten worden bij het interpreteren van de 
resultaten en naar welke patiënten de resultaten te generaliseren zijn. Ten slotte worden 
er aanbevelingen gedaan voor de klinische praktijk en voor toekomstige onderzoeken.  De 
belangrijkste aanbevelingen zijn dat er meer aandacht moet komen voor andere symptomen 
van de ziekte naast gewrichtsontsteking, dat er behandeld moet worden tot er een lage 
ziekteactiviteit behaald is en dat ziekteactiviteit het beste met een GRACE-, PASDAS- of MDA-
score berekend kan worden. 
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Dan eindelijk het makkelijkst te lezen en meest gelezen onderdeel van een proefschrift: het 
dankwoord. Het werk is gedaan, het boekje is af, maar niet zonder hulp van heel veel mensen 
die ik graag wil bedanken.  
Allereerst wil ik alle deelnemers van DEPAR en de echo-studies bedanken: zonder jullie viel er 
geen ziekteactiviteit en uitkomsten te meten. Dank voor alle tijd en energie die jullie gestoken 
hebben in de studiebezoeken en het invullen van al die vragenlijsten.  
Mijn promotor, Mieke Hazes, zonder enige uitzondering had ik na onze afspraken het gevoel 
waar het allemaal heen ging en waar ik eigenlijk mee bezig was. Dank voor al die motivatie, 
de kritische feedback, en voor al het vertrouwen wat ik zeker op het einde zo hard nodig had.  
Mijn copromotor, Marijn, ik had altijd de ruimte om te zeggen wat ik er van vond en waar het 
heen moest gaan, en ook als het niet over artikelen ging had ik het gevoel alles te kunnen 
zeggen. Dankjewel voor je optimisme en enthousiasme, en natuurlijk dankjewel voor alle lol, 
de muziekopvoeding, de Engelse verhaspelingen en de Tony Chocolonely’s.
Mijn andere copromotor, Jolanda, je dacht met me mee en legde de vinger op de zere plek als 
ik bedacht hoe we het nu weer gingen doen in de analyse. Dankjewel voor al die discussies, je 
kritische blik, en voor me uit mijn comfort-zone halen. 
De stuurgroep van DEPAR had naast mijn copromotoren nog twee leden: Ilja en later ook Marc. 
Ik heb bewondering voor alles wat jullie voor het project gedaan hebben, dankjulliewel dat ik 
een deel mocht zijn van het DEPAR-Team. Alle andere coauteurs en hoofdonderzoekers 
van alle centra: dank voor jullie hulp bij het verzamelen van alle soorten data, en voor jullie 
feedback op de artikelen.  
Zonder deelnemers viel er niets te meten, maar zonder onderzoeksverpleegkundigen en 
reumatologen ook zeker niet. Onderzoeksverpleegkundigen van de DEPAR-centra: 
dankjulliewel voor al het werk wat jullie verzet hebben om al die patiënten te zien, te zorgen 
dat ze gezien werden, ze te motiveren om al die vragenlijsten in te vullen, en natuurlijk om al 
die gegevens te verzamelen. Ik bewonder hoe jullie het allemaal gebolwerkt hebben in jullie 
drukke schema en ik voelde me altijd welkom als ik langs kwam. Aan alle reumatologen 
en reumatologen in opleiding van de DEPAR-centra: dank voor het aanmelden van al die 
patiënten en jullie betrokkenheid bij CICERO en DEPAR, en dat ik deel mocht zijn van jullie 
wetenschappelijk onderzoek. 
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Esther, de afgelopen jaren ben je van alles voor me geweest: begeleider, collega, partner in 
crime, beschermengel,  en nog heel veel meer. Zonder dat had ik oprecht niet geweest wie 
ik nu ben en gestaan waar ik nu sta (al hoor ik je nu al denken dat je het daar niet mee eens 
bent). Iedereen heeft een Esther nodig tijdens zijn promotie, dankjewel dat ik de enige echte 
originele Esther had tijdens mijn promotie. Ik ben heel blij dat ik je weer achter me heb staan, 
tijdens de verdediging. 
De rest van het DEPAR-Team: Liesbeth, Mariëtte, Anouk, Romke, Annet, en Ron, dank voor 
al jullie ICT- en coördinatiehulp. Lydia, onze eigen DEPAR-student, dankjewel voor al je harde 
werk en je zorgvuldigheid. Ook dank aan de studenten van het studententeam. 
Al mijn andere collega’s van de reumatologie: dank voor jullie gezelligheid, jullie support en 
voor de leuke tijd die we hadden. Maren, dankjewel voor alle lol, de liters en liters thee, en dat 
ik je alles mocht vragen. Myrthe, dankjewel voor alles wat ik van je geleerd heb, en ook voor 
alle gezelligheid. Annelieke, ik ben blij dat je altijd bij de reumatologie bent blijven horen, 
met je droge humor en nuchtere kijk op het leven. Hilal, jouw motivatie en vastberadenheid 
toen de eindstreep in zicht kwam hebben me heel erg geholpen aan het einde. Martijn, als 
het niet wilde lukken met de analyse of met STATA kon ik het altijd aan je vragen, zelfs toen je 
niet meer mijn collega was. Elise, Jeroen en Luis, dank voor alle therapeutische biertjes en 
gezelligheid. 
Nienke, echo-buddy, masteronderzoek-buddy, taart-buddy, ik heb zo veel bewondering voor 
jouw drive en wat je allemaal voor elkaar krijgt. Dankjewel voor alle lieve opvrolijk-pakketten, 
voor de frustraties delen, en alle lol die we gehad hebben.  
Hannah, je kwam precies op tijd met je aanstekelijke enthousiasme en doorzettingsvermogen. 
Alle goede ideeën ontstaan uiteraard op de vrijdagmiddagborrel, en ik ben ontzettend trots op 
wat we samen bereikt hebben en wat we nog gaan bereiken. 
Annelieke, we zijn het avontuur samen aan gegaan en ook al deden we totaal iets anders, ik 
heb altijd het gevoel gehad dat we het samen deden. We sleepten elkaar uit de diepe dalen en 
vierden samen alle successen, je wist altijd precies de goede dingen te zeggen. Als mijn eigen 
zorgvuldigheid me in de steek liet na de zoveelste versie van een artikel kon ik er vanop aan 
dat jij nog wel zag dat ik de afkorting in het ene onderschrift wel met hoofdletter schreef en de 
andere keer niet. Dankjewel voor alles en ik ben blij en trots dat je achter me wilt staan tijdens 
mijn verdediging. 
Mijn andere geneeskundevriendinnetjes, Anne en Carmen, dankjulliewel voor alle sauna-
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hebben. Ik mag altijd alles uit de bizarre geneeskunde-wereld met jullie delen.  Bewoners van 
villa-Heemskerk, Esther, Trevor, Suzanne, Joris en Demi, het was fijn zo veel lieve vrienden 
een deur verder te hebben wonen. Mijn Emmaus-vriendinnetjes, Marijke, Lisanne, Susan en 
Manon, we zien elkaar wat minder vaak dan vroeger maar ik ben blij dat als we elkaar zien, het 
weer precies zo is als toen. Gerbera, Jelle, Anton, Mohit en Martijn, dankjulliewel voor de 
gezellige etentjes en weekendjes weg.  
Lieve mams, dankjewel voor alles wat je voor me doet en dat je er altijd voor me bent, ik ben 
altijd welkom in hotel mama. Lieve kleine grote broertjes, Richard en Yoeri, het is altijd lachen 
met en om jullie, en ik ben trots op wat jullie bereikt hebben en ongetwijfeld zullen bereiken. 
Eric en Iris, dankjulliewel voor alle gezelligheid en spelletjesavonden. Eric, dankjewel ook 
voor al je hulp bij het ontwerp van dit proefschrift, zonder jou had het niet zo mooi geweest. 
De rest van mijn familie en schoonfamilie, dank voor jullie lieve support en interesse in wat 
ik gedaan heb, ondanks dat het af en toe moeilijk te volgen was wat ik deed en waarom. Ik kijk 
er naar uit jullie te vertellen waar ik eigenlijk al die tijd mee bezig ben geweest.
Lieve Thomas,  ik ben trots op het fijne, vertrouwde thuis wat we samen gebouwd hebben. 
Wat er ook gebeurt, je bent er voor me als ik het even niet meer weet, altijd trots, en om alle 
goede dingen te vieren. Dankjewel voor alles wat je voor me bent en alles wat ik voor je mag 
zijn.
Mischief Managed,  Kim 

